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Fluoropyrimidines in the treatment of cancer 
Fluoropyrimidines have been applied in the treatment of cancer for decades and are extensively 
used worldwide. The most known fluoropyrimidine is 5-fluorouracil (5-FU). 5-FU was 
developed in 1954 after the discovery that liver tumours absorbed radioactive uracil more 
readily than normal liver cells. Previously, Charles Heidelberger discovered that fluorine 
in fluoroacetic acid inhibited the vital enzyme aconitase that catalyzes the stereo-specific 
isomerization of citrate to isocitrate via cis-aconitate in the tricarboxylic acid cycle. Based on 
this finding that a fluorine atom causes a profound alteration in biological effect, and the fact 
that uracil in tumours is incorporated into RNA, Heidelberger substituted a hydrogen atom 
in the uracil molecule for a fluorine atom with the idea that if 5-FU were to have biological 
activity, it should block DNA synthesis [1]. These two scientific results led to the development 
of 5-FU as an anticancer drug [2].
In a clinical setting, 5-FU is administered intravenously, as a bolus or prolonged infusion or 
as a topical cream and orally. The intravenous and oral presentations of 5-FU are widely used 
in the treatment of a range of cancers such as breast cancer, cancers of the gastrointestinal 
and urogenital tract and head and neck cancer. Topical 5-FU is used in the treatment 
of actinic keratosis and Bowen’s disease. Meta-analysis of the efficacy of intravenous 
continuous infusion of 5-FU compared with bolus administration in advanced colorectal 
cancer showed that continuous infusion is superior compared to bolus infusion in terms of 
tumour response and resulted in a slightly increase in overall survival [3]. The morbidity 
associated with indwelling catheters and infusion pumps and patient inconvenience with 
regard to the length of continue infusion schemes of 5-FU led to the development of the 
oral fluoropyrimidines. Oral administration of 5-FU results in wide intra- and interpatient 
variability in 5-FU plasma levels [4]. The oral fluoropyrimdines can be divided into 3 
groups, 5-FU prodrugs; 5-FU combined with a DPD inhibitor, and 5-FU prodrugs combined 
with a DPD inhibitor [5]. The most frequently used 5-FU prodrug is capecitabine. This 
drug is first converted to 5-deoxyfluorocytidine in the liver by carboxylesterase and then 
converted to doxifluridine by cytidine deaminase, which is found in liver, plasma, and 
tumour tissue. The toxic intermediary doxifluridine is then converted to 5-FU by thymidine 
phosphorylase, that is more abundant in tumours than in normal tissue, resulting in tumour 
5-FU concentrations that far exceed plasma levels and produce greater antineoplastic effects 
with lower toxicity [6, 7]. The availability of capecitabine resulted in the Netherlands in 















cancer. In the Netherlands, approximately 90% of all fluoropyrimidine-containing therapy 
contains capecitabine. Published cost-effectiveness analysis regarding the treatment of 
stage III colon cancer shows that capecitabine is less costly and more effective than 5-FU 
treatment [8, 9], which indicates that huge cost savings are established in the treatment of 
colon cancer.  
Fluoropyrimidine mechanism of action and toxicity
In vivo, 5-FU is partly converted intracellular to the active metabolites fluorodeoxyuridine 
monophosphate (FdUMP) and fluorouridine triphosphate (FUTP) [10]. FUTP disrupts 
RNA synthesis and FdUMP inhibits thymidylate synthase (TS), which is the key enzyme in 
the de novo synthesis of thymidylate that is necessary for DNA replication and repair. TS 
catalyzes the reductive methylation of deoxyuridine monophosphate (dUMP) to thymidine 
monophosphate (TMP). The TS protein functions as a dimer with one nucleotide-binding 
site. The 5-FU metabolite FdUMP binds to this nucleotide-binding site forming a stable 
complex and thereby blocking the binding of dUMP, which results in inhibition of TMP 
synthesis [11, 12]. 
The metabolite FUTP is incorporated into RNA leading to dysfunction [3]. In cancer cell 
lines a correlation was observed between FUTP misincorporation into RNA and loss of 
clonogenic potential [13, 14]. Several in vitro studies indicated that 5-FU misincorporation 
disrupt many aspects of RNA processing leading tot profound effects on cellular metabolism 
and viability [10]. With intravenous administration, the length of infusion is correlated with 
the mechanism of action of 5-FU since the mechanism of action of bolus administration is 
mainly inhibition of TS, while continuous infusion is cytotoxic by misincorporation into RNA 
[15]. These two mechanisms of action lead to differences in type of toxicity. The results of a 
meta-analysis showed that, with 5-FU bolus, hematologic toxicity was more frequent than 
with continuous infusion (31% and 4%, p < 0.0001). On the other hand, continuous infusion 
resulted in higher incidence of hand-foot syndrome compared with bolus infusion (13% and 
34%, p < 0.0001) [3]. Incidence and proportions of all other toxicities were identical for bolus 
and continuous infusion. Independent prognostic factors were age, sex, and performance 
status for nonhematologic toxicities, performance status, and treatment for hematologic 




The rate-limiting enzyme in 5-FU catabolism is dihydropyrimidine dehydrogenase (DPD). 
More than 80% of the amount of 5-FU administered is normally catabolized primarily in 
the liver where DPD is abundantly expressed [16, 17]. DPD is also present in normal and 
tumour cells. 5-FU is converted by DPD into 5,6-dihydrofluorouracil (DHFU). Subsequently, 
DHFU is degraded into fluoro-β-ureidopropionic acid (FUPA) and fluoro-β-alanine (FBAL). 
In general, fluoropyrimidines are tolerated well although approximately 10% of the patients 
treated with fluoropyrimidines suffer from CTC grade III or IV toxicity. Interindividual 
variability in the activity of DPD can be the cause of this severe toxicity. DPD is encoded 
by DPYD and polymorphisms in DPYD have shown to be related to toxicity in colorectal 
patients treated with capecitabine and 5-FU [18-20]. In patients with a near complete DPD 
deficiency this can even lead to death [21]. Knowledge of the clinical impact of reduced DPD 
activity on the pharmacokinetics and pharmacodynamics of fluoropyrimidines may lead to 
dose individualized therapy. Therapeutic drug monitoring of 5-FU has been shown to result 
in reduced intra- and inter-individual variability in 5-FU plasma levels and pharmacokinetic 
guided dose adjustments of 5-FU-containing therapy results in a significantly improved 
efficacy and tolerability [22]. In addition, pharmacokinetic Michaelis-Menten models allows 
the use a limited sampling strategy and offer the opportunity to predict a priori the 5-FU 
plasma concentrations in patients receiving adapted doses of 5-FU [23].
Aim and outline of this thesis
The general aim of this thesis is to study the use of an oral uracil loading dose as probe 
for DPD deficiency in cancer patients treated with fluoropyrimdines and to develop a test 
procedure that is suitable to be incorporated broadly into daily practice in hospital care. 
With regard to this latter aspect, it will be studied if a prospective DPD testing strategy can 
be successfully incorporated into routine clinical healthcare as a standard procedure for all 
patients using a fluoropyrimidine.
In CHAPTER 2 a review is presented of studies that describe predictive tests developed for 
screening for DPD. This chapter outlines the status of methods for testing for DPD deficiency 
and their use in daily practice. 
In order to perform clinical tests, uracil as an investigational medicinal product must be 















required for this approval is called ‘Investigational Medicinal Product Dossier’ (IMPD) and 
includes summaries of information related to the quality, manufacture and control of the 
Investigational Medicinal Product, data from non-clinical studies and data from its clinical 
use. CHAPTER 3 is the Investigational Medical Product Dossier of uracil for the oral uracil 
loading test that was used for approval by the Medical Ethical committees of clinical trials 
described in Chapter 5, 6 and 7. 
In CHAPTER 4 the pharmacokinetics of the oral uracil loading dose in healthy volunteers and 
cancer patients is studied. Part of this study is a dose finding strategy in order to determine 
which uracil dose is optimal. This study can be considered as a phase 1 study in order to 
determine optimal dose, safety and compare results between healthy volunteers and patients. 
In this study oral uracil is administered in dosages of 500 and 1000 mg/m2 Body Surface 
Area (BSA) to healthy volunteers. This study is important to determine the most effective 
dose and to determine if disease status will influence the results of the uracil loading test.
CHAPTER 5 describes a study in which the oral uracil loading dose is administered to 
colorectal cancer patients with and without metastasis, all with normal DPD status. This 
study is performed to investigate if presence of metastases will influence the pharmacokinetics 
of oral uracil. Since the objective of the oral uracil loading dose is that is will be used 
prospectively in all patients with different types of cancer, disease status ideally does not 
influence pharmacokinetics. This is the first study in which the potential effect of metastatic 
disease on uracil pharmacokinetics in colorectal cancer patients will be investigated. 
The EURABEL2 study is described in CHAPTER 6. The aim of of this study is to develop 
a limited sampling strategy, to detect decreased uracil elimination in patients with a DPD 
deficiency and to perform a more in-depth quantitative compartmental pharmacokinetic 
analysis of uracil plasma concentrations. 
In this study patients with toxicity will be included and divided in two groups based on the 
results of the measurement of DPD activity in peripheral blood mononuclear cells (PBMCs), 
which in this study is considered to be the gold standard. The performance of the oral uracil 
loading dose in the two groups will be compared with the results of the gold standard and 
specificity and sensitivity will be calculated.
In CHAPTER 7 the results are described of a study that evaluated the clinical acceptance 
and adherence of a prospective DPYD genotyping strategy that was implemented at Leiden 
University Medical Center. The objective of this genotyping strategy is that all patients who 
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have an indication for first time treatment with 5FU or CAP are routinely prospectively 
screened for the presence of four pathogenic variants to prevent 5FU related toxicity caused 
by DPYD genetic variations. 
This thesis ends with a general discussion and future perspectives in CHAPTER 8. A sum-
mary of this thesis is presented in CHAPTER 9. 
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ABSTRACT
5-fluorouracil (5-FU) is rapidly degraded by dihydropyrimidine dehydrogenase 
(DPD). Therefore, DPD deficiency can lead to severe toxicity or even death following 
treatment with 5-FU or capecitabine. Different tests based on assessing DPD 
enzyme activity, genetic variants in DPYD and mRNA variants have been studied 
for screening for DPD deficiency, but none of these are implemented broadly into 
clinical practice. We give an overview of the tests that can be used to detect DPD 















The fluoropyrimidine 5-fluorouracil (5-FU) and its prodrug capecitabine are the cornerstone 
of treatment of numerous types of cancer. The use of fluoropyrimidines is associated with 
numerous side effects such as myelosuppression, hand-foot syndrome, mucositis, diarrhea 
and occasionally cardiac toxicity.
After parenteral administration of 5-FU, 70–90% of the parent drug is degraded by 
dihydropyrimidine dehydrogenase (DPD) [1-5]. A small proportion of patients develop 
extreme toxicity after administration of a fluoropyrimidine due to a partial or complete 
DPD deficiency and hence a strongly reduced capacity to degrade 5-FU [6-10]. In case of 
complete DPD deficiency 5FU treatment may even result in a lethal outcome [11]. It was 
initially estimated that in 3–5% of Caucasians the activity of DPD is strongly reduced due to 
(epi)genetic variations in the gene encoding DPD [4, 12]. However, this percentage has been 
disputed since there is still no consensus on the definition of DPD deficiency and therefore 
the incidence of DPD deficiency reported in numerous studies is strongly dependent on 
the method used to assess DPD deficiency [13] and the cut off level chosen to define DPD 
deficiency [5].
Prospective testing for DPD deficiency in patients might prevent DPD deficient patients from 
severe toxicity or even death. In this review, we describe current methods for determination 
of DPD deficiency. We discuss the potential and limitations of these tests for routine clinical 
use. In addition, we have defined recommendations that can help successful implementation 
of a preemptive testing strategy to predict fluoropyrimidine related toxicity.
METHODS 
To identify studies describing diagnostic tests to detect DPD deficiency a systematic 
MEDLINE, EMBASE, Web of Science and Cochrane search was conducted using the 
following combination of (MESH) terms: “dihydropyrimidine dehydrogenase deficiency”, 
“dpd deficiency”, “Familial Pyrimidinemia”, ”uracil”, ”capecitabine”, “dihydrouracil 
dehydrogenase (nadp)”, “dihydrouracil dehydrogenase”, “dihydropyrimidine dehydrogenase”, 
“dihydrouracil dehydrogenase (nad+)” and ”dpd”. The unique hits collected from these 
databases were selected and further limited to English language papers from 1980 to 
December 2015. Papers describing studies aimed at testing DPD activity and/or DPD 
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deficiency in volunteers or patients were selected. Cross-references were identified from 
bibliographies from the selected studies. Only articles that describe the complete performance 
of the test were included, reviews and papers describing in vitro studies including DPD 
activity in cancer cells or studies in animals were neglected. The collected publications 
were divided into three categories; describing tests aimed at assessing DPD enzyme activity, 
genetic variants in DPYD and mRNA variants.
RESULTS 
Tests aimed at assessing (surrogates for) DPD enzyme activity
Several tests have been described to assess the activity of the enzyme DPD. 
DPD activity in peripheral blood mononuclear cells (PBMCs)
The majority of DPD is reported to be in the liver [1, 14] but DPD activity in other tissues 
such as lymphocytes contribute to metabolism of fluoropyrimidines as well [15]. The liver 
DPD activity in patients revealed a strong correlation with DPD activity in peripheral blood 
mononuclear cells (PBMCs) [16]. The mean DPD activity in PBM cells of patients with a 
partial DPD deficiency, is approximately 48% of that observed in the normal population 
due to heterozygosity for a pathological mutation [17]. The methodology of the test includes 
incubating isolated lymphocytes with radioactive labeled 5-FU or thymine after which the 
degradation products are measured by high-performance liquid chromatography (HPLC) 
with a radioisotope flow detector [2, 18-20]. A HPLC-electrospray tandem mass spectrometry 
(HPLC MS/MS) method has also been developed [17, 21]. The use of a porous graphitic 
carbon (PBC) column [22] results in a HPLC process that is highly pH stable compared 
to the reversed-phase C-18 column and the detection limit was at least similar to the C-18 
columns with considerably shorter analysis time. This method was validated (Table 2.1). 
Evaluation of the stability of DPD in PBMCs indicated that the DPD activity decreased 
approximately 50% upon freezing, but was stable for at least 1 month [16]. The stability of 
radioactive 5-FU and its metabolite dihydrofluorouracil (DHFU) in the reaction mixture 
was found to be stable for three months and not affected by at least three freeze-thawing 
cycles [19]. The use of an on-line radioisotope flow detector makes this method very useful 
as a semi-automated radioassay but the specific equipment that is necessary might hamper 
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systemic 5-FU clearance has been studied but the results are contradictive. One study found 
a good correlation [2] but two other studies found a much poorer relation [4, 23]. Instead of 
radiolabeled substrates, the use of nonradiolabeled thymine as substrate was investigated [17]. 
Nevertheless, because of the superior sensitivity of radiochemical assays, the presence of a 
complete DPD deficiency can be established only with the DPD assay that use radiolabeled 
substrates [18, 19, 22]. The distinction between a partial and complete DPD deficiency is 
important to make because in the case of a partial deficiency the oncologist might consider 
dose reduction. Complete DPD deficiency may lead to switching to a non fluoropyrimidine 
containing regimen. In general, the assays to measure DPD activity in PBMCs are labor 
intensive and therefore expensive. For this reason it is not likely that this method is suitable 
to use broadly into clinical practice. 
Uracil breath test
The principle of this test is that after ingestion of an aqueous solution of 2-13C-uracil (6 
mg/kg), degradation of 2-13C-uracil by DPD followed by the other two enzymes of the 
pyrimidine degradation pathway takes place resulting in the production of 13CO
2
 [24-27] 
which is determined in exhaled breath using IR spectroscopy (UBiT-IR300). In DPD deficient 
individuals, reduced 2-13C-uracil catabolism results in decreased exhaled 13CO
2
 levels. The 
amount of 13CO
2
 present in breath samples is expressed as δ over baseline (DOB) ratio that 




 ratio of breath samples collected before and after 
2-13C-uracil ingestion. The breath test was evaluated in multiple studies with volunteers and 
cancer patients with or without (partial) DPD deficiency and has been extensively validated 
(Table 2.1), but sensitivity and specificity show considerable variation between the studies 
performed. One study compared the plasma 2-13C-uracil pharmacokinetics with expired 
13CO
2
 in subjects with normal and reduced PBMC DPD activity [25]. The results of this 









The breath test is rapid and non-invasive since it only requires exhaled air from patients, 
which is collected into sealed bags that are transported to a central laboratory. The integrity 
of the breath collection bags was stable for up to 201 days after their initial examination. 
However, the transportation may delay the availability of outcome of the test result for the 
physician, possibly delaying the start of chemotherapy. A broad clinical use of this test is 
further hampered by the limited availability of the expensive 2-13C-uracil and the fact that 
the UBiT-IR
300
 spectrophotometer that is needed for the analysis is not common available 














Endogenous U/DHU or DHU/U ratio
Besides the ex vivo measurement of DPD activity in human cells, alternative assays have 
been developed including the analysis of endogenous uracil (U) and/or dihydrouracil (DHU) 
levels or their ratio in plasma [28-36], urine [20, 37, 38] or saliva [39]. In case of a (partial) 
DPD deficiency the breakdown of uracil is impaired causing elevated endogenous uracil 
levels and decreased dihydrouracil levels in biological fluids such as plasma or urine. U an 
DHU can be measured by HPLC [40] and GC [29] methods which have been validated 
(Table 2.1). A strong correlation was detected between the DHU/U ratio in plasma with 
5-FU half-life, clearance and plasma levels [28, 31, 33]. However, it was reported that in 
some individuals with a normal U/DHU ratio strongly elevated 5-FU levels were measured 
indicating that determination of the U/DHU ratio may not always correctly reflect 5FU 
levels [41]. Interestingly, in one of the studies it is suggested that the U/DHU plasma ratio 
might only be predictive during 5-FU treatment when DPD is saturated and not at baseline 
when DPD is nonsaturated [35]. The stability of uracil in plasma is at least 2 months at 80°C 
[29]. A significant circadian rhythm in plasma and urine DHU/U ratio and DPD activity 
in mononuclear cells was observed in healthy subjects, but this was disrupted in patients 
who were continuously infused with a high dose of 5-FU [42]. The biological significance 
of the DPD circadian pattern to fluoropyrimidine drug treatment is obvious, since the 
variations in DPD between individuals can result in 5-FU concentration fluctuations that 
can be directly correlated with treatment toxicity. The circadian rhythm in a population 
of patients and volunteers should be investigated to determine threshold values for those 
patients who are prone to toxicity. The good stability of uracil in plasma and the fact that 
the HPLC equipment needed for this assay is available in most clinical laboratories, make 
this method suitable for broad clinical implementation. 
5-FU Therapeutic Drug Monitoring
The pharmacokinetics of 5-FU and its metabolite DHFU can be assessed to detect possible 
DPD deficiency. The determination of plasma concentrations of 5-FU and DHFU can be 
performed by HPLC [30, 43-45], LC-MS/MS [46] or immunoassay [47]. These methods 
have been validated (Table 2.1) [30, 43, 47]. Based on this principle, several investigators 
hypothesized that the administration of a test dose of 5-FU before the start of chemotherapy 
might enable identifying subjects at risk of severe treatment-related side effects [9, 43, 44, 
48-51]. The test doses 5-FU investigated ranged from 250 mg/m2, 300 mg/m2, 370 mg/m2 
to 450 mg/m2 after which 5-FU and DHFU were measured in plasma. The pharmacokinetic 
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results following a test dose of 250 mg/m2 5-FU were significantly different from a dose of 370 
mg/m2 [49], but there was no linear correlation between 5-FU and DHFU pharmacokinetics 
and no correlation between DPD activity and 5-FU pharmacokinetics following a dose of 
250 mg/m2. In one study test doses of 300 mg/m2 or 450 mg/m2 were used in subjects with 
and without the presence of the c.1905+1G>A (IVS14+1G>A) mutation [51]. Only with 
the dose of 450 mg/m2, the mean AUC and clearance of 5FU was significantly different, 
but the terminal half-life of 5-FU measured at both test doses showed a highly significant 
difference. A limited sampling model based on two time points was studied in patients 
receiving 370 mg/m2 5-FU as an iv bolus making the test more suitable for clinical practice 
and less patient intensive [50]. More recently, a validated limited sampling two compartment 
PK model was presented based on a single sample after 300 or 450 mg/m2 5-FU. Normal and 
DPD deficient patients could be discriminated at 300 mg/m2 [9]. In line with these results, 
a three compartment model for 5-FU and 5 fluoro-5,6-dihydrouracil was developed using 
retrospectively PK data from 127 colorectal cancer patients treated with 5-FU bolus infusion 
[52]. The model that was developed has significant potential to identify patients with the 
decreased DPD phenotype requiring earlier adjustment of the 5-FU dose. The principle of 
a PK modeling approach is simple and might be promising. A potential disadvantage of 
the test dose of 5-FU is that it might cause toxicity in severely deficient DPD patients (i.e. 
homozygous DPD deficient). One study showed no toxicity in 20 of 22 patients heterozygous 
for the c.1905+1G>A after the administration of the single doses of 5-FU 300 and 450 mg/
m2 [9]. However possible toxic reactions following a 5-FU test dose in severely deficient 
patients should be studied further in a larger population.
Oral thymine administration
Thymine (5-methyluracil) is catabolized by the same enzymatic pathway as 5-FU and was 
investigated as a probe to detect carriers of DPD and dihydropyrimidinase deficiencies 
[53]. Oral powdered thymine was administrated encapsulated in a dose of 250 mg in the 
morning. At pre-set points, blood samples were drawn. 
Plasma and urine concentrations of thymine, dihydrothymine can be measured with the 
use of a validated rapid method based on LC-MS/MS [54]. The oral thymine test is at this 
moment no candidate to be used to detect DPD deficiency since it is only used in 12 healthy 
volunteers with no DPYD variants and not in cancer patients with or without DPD deficiency. 














Tests aimed at assessing genetic variants in DPYD, the gene encoding DPD
Polymerase Chain Reaction (PCR)- Denaturing High-Performance Liquid Chromatography 
(DHPLC)
DPD is encoded by the DPYD gene and there is an increased incidence of 5-FU and 
capecitabine related toxicity when pathological DPYD variants are present [45, 55-63]. Based 
on the evidence from the published literature dosing recommendations for fluoropyrimidines 
based on genotype are recommended [64-66]. One possible method to detect DPYD 
mutations involves Denaturing High-Performance Liquid Chromatography (DHPLC) 
[55, 67-69]. This assay is based on temperature-depending separation of DNA containing 
mismatched base pairs from a pool of Polymerase Chain Reaction (PCR)-amplified 
DNA fragments. This method is highly sensitive and can detect heterozygous variants. 
Homozygous wildtype vs. homozygous mutated sequences are not really resolved by this 
method. To detect homozygous mutations, mixing of each sample with a wildtype sample 
is necessary. For sequencing samples with aberrant peak patterns it is necessary to finally 
determine the kind of mutation with the use of a secondary test, which will increase total 
cost. DHPLC can be used to detect currently unrecognized unknown sequence variations 
in the DPYD gene. The DNA is isolated out of blood obtained by a single venapuncture. It 
takes approximately 250 min to screen the DPYD gene for mutations at one temperature 
[67]. A drawback of the DHPLC method is that it is laborious and time consuming, and for 
that reason not suitable for large numbers of patients. Secondly, the equipment that is used 
is not available in every hospital laboratory. With this technique the 23 DPYD exons were 
screened in DNA samples of randomly selected individuals, DPD deficient patients and 
patients who experienced toxicity following 5-FU treatment [67-69]. Missense mutations in 
the DPYD gene will not necessary lead to reduced DPD activity. Gross et al. [69] analyzed 
DNA of 4 individuals with symptoms of 5-FU-related toxicity and compared the data to 
control samples of 157 healthy individuals. Several missense mutations were found in the 
DNA of the patients but only in one patient with 4 mutations a lower DPD activity in PBMCs 
was found. This result displays a general problem that can be found with genotyping and 
5-FU related toxicity. For a good predictive value there has to be a clear correlation between 
genetic variants and its effect on DPD activity or the likelihood to develop toxicity. A solution 
to encounter this problem is to determine the impact of novel mutations found in the DPD 
gene on enzyme activity [69-71]. 
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Pyrosequencing
Pyrosequencing [72-78] is based on the utilization of ATP to produce light. The 
pyrosequencing reaction results in the release of a pyrophosphate molecule with the 
sequential incorporation of bases to the DNA template. The technique is developed in to a 
fully automated process as a result of advanced equipment that allows genotyping of multiple 
samples within an hour. However, the initial investment in the equipment is around 50,000–
80,000 Euro and as a result it is not available in every hospital laboratory. The technique of 
pyrosequencing and its role in detecting mutations in the DPYD gene has been extensively 
studied in volunteers and cancer patients. In a population of 14 individuals with a reduced 
DPD activity and severe 5-FU related toxicity, 57% had a molecular basis for their deficient 
phenotype [76]. Three DPYD variants, the c.1905+1G>A (IVS14+1G>A), c.2846A>T, and 
c.1236A>T were strongly associated with fluoropyrimidine-induced toxicity [72, 77, 78]. In a 
large population of 487 patients, one-third of the patients with one of the SNPs had no adverse 
reactions, and therefore the presence of a SNP will not automatically imply development 
of toxicity following 5-FU therapy. Interestingly, the absence of a SNP will also not exclude 
developing toxicity since in several studies patients were identified that had no SNP but still 
suffered from severe initial side effects as a result of a lowered 5-FU plasma clearance [73, 
79, 80]. The determination of a single SNP can be easily performed in hospital settings and 
costs at this moment around 25 Euros per SNP. Determination of multiple clinically relevant 
SNPs could potentially enhance sensitivity and specificity. Pyrosequencing is used on more 
and more in daily practice prior to 5-FU administration despite the lack of prospective 
evidence of its usefulness. Like all PCR based tests, a disadvantage of pyrosequencing is 
that with this method only SNPs and small deletions are detected. Large genomic deletions 
are missed and especially those are present in the DPD gene [77].
Restriction Fragment Length Polymorphism (RFLP)
RFLP is a technique in which DNA is spliced into fragments by restriction enzymes. 
Following the splicing, the DNA fragments are separated by gel electrophoresis. RFLP has 
been used in studies that investigated the presence of the c.1905+1G>A mutation in cancer 
patients with 5-FU related toxicity [11, 81]. 
Single-strand conformation polymorphisms SSCP
SSCP is a technique that was also optimized to be useful for pharmacogenetic DPD studies, 














in the secondary structures in single-strand DNA fragments caused by a change in sequence, 
which are detected as alterations in fragment mobility by gel electrophoresis. The conditions 
of SSCP were optimized with an automated system to screen genetic polymorphisms in 
the DPYD gene and its efficacy was evaluated by using 21 DNA samples with previously 
characterized polymorphisms [82]. The polymorphism detection rate of this technique 
was 95.3%. 
Epigenetics
Since the observation in several studies, that DPYD sequence variants could not fully explain 
the molecular basis of DPD deficiency, it is hypothesized [83, 84] that methylation of the 
DPYD promoter might be an alternative mechanism for DPD deficiency in cancer patients. 
Methylation of CpG islands located in the 5’-regulatory region of the DPYD gene has been 
shown to inhibit transcription [83]. The methylation status of DNA fragments can be detected 
with the use of DHPLC or with pyrosequencing. One study showed a significant association 
between aberrant methylation of the DPYD promoter and DPD enzyme deficiency in 80% 
of DPD-deficient individuals, whereas all individuals with normal DPD enzyme activity 
tested negative for methylation [83]. In contrast, other studies did not confirm the role 
of DPYD promoter hypermethylation to development of severe 5-FU toxicity [85, 86]. 
The contradictory results of the studies investigating the role of methylation of the DPYD 
promoter make it unlikely that screening for aberrant methylation of the promoter of DPYD 
will become current practice soon.    
Tests aimed at assessing mRNA variants encoding DPD
DNA mutations can result in altered mRNA levels or aberrant splicing of the pre-mRNA. It 
is hypothesized that DPD enzyme activity is possibly correlated with DPD mRNA expression 
[87]. Using a reverse transcription-PCR-based assay, the exon 14 skipping mutation has been 
studied in patients with and without grade 3-4 toxicity following 5-FU therapy [88]. The 
DPD enzyme activity correlated with DPD mRNA expression in biopsy-sized tissue samples 
including peripheral blood mononuclear cells [89]. A disadvantage of mRNA screening is 
the instability of mRNA in blood, which makes it unsuitable for routinely screening since 
the equipment needed for mRNA screening is not widely available in every hospital. For 
this reason it is unlikely that this technique is suitable for prospective screening of large 
amounts of patients.
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DISCUSSION
Predicting toxicity
The concept of the tests described in this review is that DPD deficiency results in decreased 
5-FU clearance leading to a higher incidence of side effects. However, some patients that 
suffer from severe side effects caused by 5-FU show normal 5-FU pharmacokinetics or 
wildtype DPYD genotype and for this fact it is important to realize that prospective testing 
for DPD deficiency will not exclude all 5-FU related toxicity. 
Sensitivity and specificity
Tests at the DNA and RNA may assess the presence of certain known mutations in the DPYD 
gene. However, new and undetected mutations are missed. Analysis of the prevalence of 
the various mutations in the DPD gene (DPYD) revealed that three mutations, of which 
two in non coding areas, c.1905+1G>A (IVS14+1G>A), c.2846A>T (p.D949V) and 
c.1129-5923C>G were most commonly involved with toxicity [5, 11, 72, 77, 78, 80, 90]. 
Unfortunately, fluoropyrimidine toxicity is only partly explained by mutations in the coding 
region of DPYD [77]. With respect to overall toxicity, the sensitivity for screening for only 
the c.1905+1G>A mutation was only 5.5 % [91] and 31% for c.1905+1G>A (IVS14+1G>A), 
c.2846A>T (p.D949V) and c.1679T>G [80]. Until now, only coding areas and flanking 
intron sequences have been analyzed, though deep intron mutations might influence the 
splicing of DYPD pre-mRNA, as was demonstrated recently [77]. In the case of a test to 
detect DPD deficiency, sensitivity should be as high as possible. Low specificity of a test 
might lead to unnecessary dose reduction and non-optimal therapy in false positive cases. 
A solution for this might be to develop a 5-FU dose escalation model [92] but this has not 
been investigated yet.
Definition of DPD deficiency
Among the tests described, there is wide variation in the definition of DPD deficiency that 
is used. The lack of a clear definition of DPD deficiency might hamper the implementation 
of prospective screening on a broad scale. With phenotyping, a patient is considered to be 
DPD deficient if the DPD activity is below a subjective pre-set threshold value. DPD activity 














sub-fractions of blood cell components that can be variable [93]. With genotyping studies, 
DPD deficiency is often defined as he presence of one or multiple SNPs. 
Cost effectiveness
The cost-effectiveness aspects of methods that might be used for prospective screening for 
DPD deficiency are sparsely described in the literature. In most countries hospital costs 
are paid by government or social healthcare systems so it is because of social-economic 
reasons that the increase of costs should be as low a reasonable achievable. The prevalence 
of partial DPD deficiency in Caucasian population is approximately at least 3% [4, 12, 80]. 
As a result many patients need to be screened preemptive in order to diagnose those with 
DPD deficiency. The costs of prospective testing ideally must be in favor to the costs of 
treatment of toxicity due to DPD deficiency that is prevented by prospective screening. 
Recently it was shown that for DPYD*2A genotype dosing of fluoropyrimdines, average 
total treatment cost per patient was lower for screening as compared to nonscreening, 
outweighing screening costs [94]. 
Based on the characteristics of the tests described, the technique of genotyping is more simple 
and less patient invasive than the phenotyping tests. The main problem with genotyping 
is the sensitivity and specificity. The determination of multiple SNPs with high prevalence 
might enhance sensitivity. Phenotyping tests for now seem to have a better correlation with 
the occurrence of 5-FU toxicity, but as with the genotyping strategy, sensitivity and specificity 
have to be established and improved. 
In order to improve broad clinical implication of a diagnostic test to detect DPD deficiency, 
we recommend that the following points in the nearby future should be taken into account:
• To enhance sensitivity of preventing fluoropyrimidine toxicity, future stu-
dies should investigate the optimization of the genotyping strategy and if 
the combination with a phenotyping test will enhance further detection of 
DPD deficient patients. 
• Following the determination of effectiveness of a test, future studies regar-
ding this test should specific focus on the cost-effectiveness. 
• A consensus definition of DPD deficiency has to be derived internationally 
to establish incidence of DPD deficiency and to compare study results.  
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• Sensitivity and specificity in relation with the prevention of fluoropyri-
midine related toxicity of every test have to be determined to measure the 
predictive outcome of establishing toxicity following 5-FU or capecitabine 
containing therapy.
In conclusion, several predictive tests are available to screen patients for DPD deficiency 
before their first treatment with fluoropyrimidines in a rapid and possibly low invasive way. 
At this moment the challenge is to optimize the tests and to determine which test strategy is 
most suitable to predict patients at risk of developing fluoropyrimidine related toxicity caused 
by DPD deficiency and to incorporate preemptive screening broadly into daily routine. 
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Investigational Medicinal Product 

















The Investigational Medicinal Product Dossier (IMPD) is the basis for approval of clinical 
trials by the competent authorities in the EU [1]. The IMPD includes summaries of 
information related to the quality, manufacturing and control of the Investigational Medicinal 
Product, data from non-clinical studies and from its clinical use. An overall risk-benefit 
assessment, critical analyses of the non-clinical and clinical data in relation to the potential 
risks and benefits of the proposed study are essential parts of the IMPD. In certain situations, 
e.g. where the Investigational Medicinal Product has already been authorised as a medicinal 
product in one of the EU Member States or when clinical studies with the IMP have already 
been approved by a Member State, a simplified IMPD will be sufficient.
The Clinical Trials Directive (2001/20/EC) came into force in April 2001, harmonizing 
the laws, regulations and administrative provisions of the Member States relating to the 
implementation of Good Clinical Practice (GCP) in the conduct of clinical trials on medicinal 
products for human use. Member States were obliged to transform the requirements outlined 
in the Directive into the respective national laws by May 2004. The Directive introduced a 
harmonized procedure for the authorization to perform a clinical study in any one of the 
EU Member States. In addition, it defines the documentation to be submitted to the Ethics 
Committee as well as the IMPD to be submitted to the competent authority for approval. 
Thus, an IMPD is requested whenever the performance of a clinical study in any one of the 
EU Member States is intended [1].
Since uracil has no marketing authorization, an IMPD is required to perform clinical studies 
with the oral uracil loading dose.
METHODS 
Based on the IMPD template [2], all paragraphs were written for uracil. All tests considering 
impurities, assays and quality were performed by an analytical monograph with the use 
of liquid chromatography with UV photo diode array detection. Acceptance criteria were 
derived from the European Pharmacopeia General Monograph 04/2013 Substances for 
Pharmaceutical Use, H5.10 Control of impurities in substances for Pharmaceutical Use and 
H2.2.46 Chromatographic Separation Techniques. All tests were performed at the laboratory 
of the Hospital Pharmacy Meppel-Hoogeveen. The manufacturing of the study drug was 
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performed by the Hospital Pharmacy Haagse Ziekenhuizen under Good Manufacturing 
Practice and Good Clinical Practice conditions. Chemical data about uracil and its synthesis 
route was derived from the supplier and safety data was derived from published animal 
studies. All studies were performed with an oral powder formulation.
1. Directive, C.T. IMPD. 2006 08.08.2006; Available from: http://www.impd.eu.
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CHEMICAL PHARMACEUTICAL AND BIOLOGICAL DATA
1. Introduction 
This clinical trial application presents information relating to uracil oral powder in dosages 
of 700, 800, 900, 1000, 1100 and 1200 mg. Uracil is an endogenous compound, and is used 
as a substrate for phenotyping of dihydropyrimidine dehydrogenase (DPD). DPD is a 
key metabolizing enzyme in the metabolic pathway of 5-fluorouracil. Patients with DPD 
deficiency are at high risk to develop severe toxicity after treatment with 5-fluorouracil 
or capecitabine. Pre-chemotherapy phenotyping of DPD with uracil may be a feasible 
method for patient screening. Uracil has been evaluated in several clinical studies [1-6] 
involving healthy subjects to evaluate the safety and tolerability profile and to assess the 
pharmacokinetic behaviour of the compound. In one of these studies, uracil was administered 
orally to 12 healthy individuals in a dose of 500 mg/m2. No unintended effects or adverse 
effects were reported during or after the administration. In 4 of these subjects uracil was 
also administered in a dose of 1000 mg/m2 [5]. No adverse events were reported. In addition 
uracil was administered to 8 patients with proven DPD deficiency in a dose of 500 mg/m2. 
Physical observation of the patients after administration did not reveal any unexpected side 
effects or unintended effects [6]. 
2.1 Chemical pharmaceutical data
2.1.S Drug substance
2.1.S.1 General information
Uracil is a common naturally occurring pyrimidine [7]. Uracil was originally discovered 
in 1900 and it was isolated by hydrolysis of yeast nuclein that was found in bovine thymus 
and spleen, herring sperm, and wheat germ [8]. Uracil is a planar, unsaturated compound 
that has the ability to absorb light [9].
2.1.S.1.1 Nomenclature
Uracil
























Molecular mass: 112.09 g/mol
2.1.S.1.3 General properties 
Stereochemistry: Not applicable
Description: White to slightly yellowish crystalline powder
Melting range: 335ºC
Hygroscopicity: Uracil is not hydroscopic
pKa (acidic): 9.45
Solubility:  Freely soluble in hot water, sparingly in cold water (100 parts of water 
at 25ºC dissolves 0.358 part of uracil). Almost insoluble in alcohol, 




Ha nsaallee 159 
D-40549 Düsseldorf 
Germany 
Figure  3.1 Uracil chemical structure. 
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2.1.S.2.2 Description of manufacturing process and process controls 
The uracil used in this study was synthesized by the condensation of maleic acid with urea 



















 + 2 H
2
O + CO
Re l ated substances from the synthesis pathway, as supplied by the manufacturer, are listed 
in Table 3.1.
2.1.S.2.3 Control of materials 
Table  3.1 Reagents, solvents and other materials
Material Grade Specific test item Possible impurity
dl-maleic acid unknown no Yes
Urea unknown no Yes
Sulphate unknown no Yes
Methanol-sodium unknown no Yes
Ethyl formate unknown no Yes
2.1.S.2.4 Controls of critical steps and intermediates 
Unknown / Not available.
2.1.S.2.5 Process validation and/or evaluation 
Unknown / Not available.
2.1.S.2.6 Manufacturing process development 














2.1.S.3.1 Elucidation of structure and other characteristics 
Each batch of uracil is identified by infra red absorption spectrophotometry. The spectrum 
obtained is compared with a uracil reference standard.
2.1.S.3.2 Impurities 
Each batch of uracil is tested on related substances by liquid chromatography with UV photo 
diode array detection. The sum of areas of any peak corresponding to impurities may not 
be greater than 1.0%. Furthermore each batch is tested for heavy metals (< 10 ppm) and 
loss on drying (< 0.5%).
2.1.S.4 Control of drug substance
2.1.S.4.1 Specification
Batches of the active ingredient will comply with the below specification (Table 3.2). Batches 
will be released only if the impurity profiles can be supported by available non-clinical data.
Table  3.2 Specifications for URACIL drug substance
Attribute Method Acceptance criteria
Appearance
Dissolution, pH and 
appearance
Visual observation
0.35 g in 100 ml water
White crystalline powder
Conforms colour reference test
pH = 5.0–5.5
Identification IR Absorption Conforms to the reference spectrum Figure 3.2









Water Ph.Eur., loss on drying ≤ 0.5%
Residue on ignition PhEur ≤ 0.10%
Assay HPLC 99.0 to 101.0%
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         Mr 112.09
CAS [66-22-8].
DEFINITION
Uracil contains not less than 98.0 percent and not more than the equivalent of 102.0 percent 
of 2,4(1H,3H)-pyrimidinone, calculated with reference to the dried basis.
CHARACTERS
A white or almost white, crystalline powder, freely soluble in hot water, sparingly in cold 
water. Almost insoluble in alcohol.
IDENTIFICATION
Examine by infrared absorption spectrophotometry (Ph.Eur. 2.2.24), comparing with the 
spectrum obtained with uracil reference standard.
TESTS
Solution S. Dissolve 0.35 g in hot carbon dioxide-free water R and dilute to 100 ml with the 
same solvent. 
Appearance of solution. Solution S is clear (2.2.1) and not more intensely coloured than 
reference solution BY7 or Y7 (2.2.2, Method II).
pH (2.2.3). The pH of solution S is 5.0 to 5.5.
Related substances. Examine by liquid chromatography (2.2.29). 
Test solution. Dissolve 0.10 g of the substance to be examined in water R and dilute to 100.0 
ml to obtain a solution having a known concentration of about 1 mg per ml.
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Reference solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with water R.
Reference solution (b). Dilute 1.0 ml of reference solution (a) to 10.0 ml with water R.
Reference solution (c). Dissolve 25 mg of dihydrouracil reference standard plus 25 mg of 
5-fluorouracil reference standard and 25 mg of uracil reference standard in water R and 
dilute to 100.0 ml. 
The chromatographic procedure may be carried out using:
• A stainless steel column 0.250 m long and 4 mm in internal diameter packed 
with octadecylsilyl silica for chromatography R (5 μm), 
• As mobile phase at a flow rate of 0.8 ml per minute a mixture 99 parts 1.5 
mM phosphate buffer (pH 5.8) and 1 part methanol R,
• As detector a spectrophotometer set at 205 nm.
Inject 20 μl of reference solution (c). Adjust the sensitivity of the system so that the heights 
of the three peaks are not less than 20 percent of the full scale of the recorder. The test is 
not valid unless the resolution between the first and second peak and between the second 
and third peak is less than 2.5. Inject 20 μl of test solution, 20 μl of reference solution (a) and 
20 μl of reference solution (b). Continue the chromatography for three times the retention 
time of uracil. In the chromatogram obtained with the test solution: the sum of the areas 
of any peaks corresponding to impurities is not greater than the area of the principal peak 
in the chromatogram obtained with reference solution (a) (1.0 percent); the area of any 
peaks corresponding to dihydrouracil and 5-fluorouracil is not greater than the area of the 
principal peak in the chromatogram obtained with reference solution (b) (0.1 percent) and 
the sum of the areas of such peaks in not greater than three times the area of the principal 
peak in the chromatogram obtained with reference solution (b) (0.3 percent). Disregard any 
peak with an area less than 0.2 times of the principal peak in the chromatogram obtained 
with reference solution (b).
Heavy metals (2.4.8). Use a platinum crucible. 1.0 g complies with limit test C for heavy 
metals (20 ppm). Prepare the standard using 2 ml of lead standard solution (10 ppm Pb) R. 
Loss on drying (2.2.32). Not more than 0.5 percent, determined on 1.000 g by drying in 














Test solution. Dissolve 0.10 g of the substance to be examined in water R and dilute to 100.0 ml. 
Test solution (a). Dilute 1.0 ml of the test solution to 100.0 ml with water R.
Reference solution. Dissolve 0.10 g uracil reference standard in water R and dilute to 100.0 
ml with the same solvent.  
Reference solution (a). Dilute 1.0 ml of the reference solution to 100.0 ml with water R.
The chromatographic procedure may be carried out using:
• A stainless steel column 0.250 m long and 4 mm in internal diameter packed 
with octadecylsilyl silica for chromatography R (5 μm), 
• As mobile phase at a flow rate of 0.8 ml per minute a mixture 99 parts 1.5 
mM phosphate buffer (pH 5.8) and 1 part methanol R,
• As detector a spectrophotometer set at 266 nm.
Inject 20 μl of test solution (a) and 20 μl of reference solution (a), record the chromatograms, 



















 are the uracil peak responses obtained from the test solution and the reference solution 
respectively.
STORAGE
Store in tight, light-resistant containers.
2.1.S.4.3 Validation of analytical procedures
Standard Operating Procedure: Validation chromatographic analytical methods ZAMH, 
version 4.
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2.1.S.4.4 Batch analyses 
One batch is purchased so far for clinical testing. The batch analyses from the producer 
are shown below: 




Assay Min. 98% 99.75%
Loss on drying Max. 0.5% 0.15%
Heavy metals Max. 10 ppm < 10 ppm
Residue on ignition Max. 0.2% 0.05%
 2.1.S.4.5 Justification of specification
The uracil analytical monograph is partly based on the Ph.Eur. monograph of 5-fluorouracil, 
and partly on specifications supplied by the manufacturer.
2.1.S.5 Reference standards or materials 
The reference standard, Uracil Lot 41K3648 was purchased from Sigma-Aldrich Inc. No 
additional recrystallization or purification was performed.
2.1.S.6 Container closure system 
The uracil powder is shipped and stored in bag stored in an airtight container.
2.1.S.7 Stability 
Uracil is very stable under normal temperatures and pressures. Uracil is not compatible with 
strong oxidizing agents. Hazardous polymerization has not been reported.
Uracil undergoes keto-enol tautomeric shifts because of its resonance structures due to the 
NH2 substituents and OH substituents. Also because any nuclear instability the molecule 
may have from the lack of formal aromaticity is compensated by the cyclic-amidic stability 













to as the lactim structure. These tautomeric forms are predominant at pH = 7. The lactam 
structure is the most common form of uracil.
Figure  3.3 Tautomeric forms of uracil. 
2.1.P Medicinal product 
2.1.P.1 Description and composition of URACIL ORAL POWDER
The qualitative compositions of uracil oral powder filled in flasks is listed in Table 3.4. 
Table  3.4 Qualitative composition of URACIL oral powder 700, 800, 900, 1000, 1100, and 1200 mg
Component Reference to standards Function
URACIL Uracil Lot 41K3648 Active ingredient
Brown plastic bottle, 300 mL Ph.Eur. Container
2.1.P.2 Pharmaceutical development
The formulation used for the clinical trials is uracil powder without additives. In previous 
clinical studies the same formulation was used.
2.1.P.2.1 Components of the medicinal product
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2.1.P.2.2 Medicinal product
Not applicable.
2.1.P.2.3 Manufacturing process development
No development information needs to be provided.
2.1.P.2.4 Container closure system
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2.1.P.3.2 Batch formula 
This information does not have to be provided.
2.1.P.3.3 Description of manufacturing process and process controls 
The production process involves the weighing of uracil powder directly in the container. 
Only one dosage strength (700, 800, 900, 1000, 1100 or 1200 mg) is produced in each 
batch. The production takes place under GMP conditions. All containers comply with the 













2.1.P.3.4 Controls of critical steps and intermediates
The weighing of the powder is double checked by two persons. The total batch is released 
by a qualified person.
2.1.P.3.5 Process validation and/or evaluation
All equipment, documents and procedures used for manufacturing comply with GMP 
standards.





2.1.P.4.3 Validation of analytical procedures
Not applicable.
2.1.P.4.4 Justification of specifications
Not applicable.
2.1.P.4.5 Excipients of human or animal origin
Not applicable.
2.1.P.4.6 Novel excipients 
Not applicable.
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2.1.P.5 Control of medicinal product 
2.1.P.5.1 Specifications (s)
Clinical trial batches of URACIL oral powder 700, 800, 900, 1000, 1100 and 1200 mg will 
meet the following specifications.
Table  3.5 Release and shelf-life specifications for Uracil oral powder in glass containers
Test item Method Acceptance criteria
Description Visual observation White powder in brown colloured fl ask 
Identifi cation IR spectrophotometry The product IR spectrum is identical to that of 
the reference spectrum
Content Uniformity Weighing Conforms to Ph. Eur.
2.1.P.5.2 Analytical procedures 
Document ID: Uracil in plasma with use of HPLC.
Document ID: Standard Operating Procedure uracil with use of (U)HPLC.
2.1.P.5.3 Validation of analytical procedures 
Document ID: Validation chromatographic analytic methods ZAMH, version 4.
2.1.P.5.4 Batch analyses 
Not applicable.
2.1.P.5.5 Characterization of impurities 
Since the active substance is used without additives and no further processing is performed 
on the uracil powder, no characterization of impurities is performed in the final product.















The reference standard, Uracil Lot 41K3648 was purchased from Sigma-Aldrich Inc. No 
additional re-crystallization or purification was performed.
2.1.P.7 Container closure system 
The uracil powder is filled in brown plastic 300 mL bottles. 
2.1.P.8 Stability 
The stability data for the drug substance show that uracil is intrinsically very stable.
There is no indication that any degradation occurs during storage is closed polypropylene 
containers.
Stability of uracil solution of 3 mg/ml in water was tested at 30, 50 and 70ºC for one week 
showing stability of concentration (vc 2.3). The shelf life of an uracil solution in water of 3 
mg/ml was tested for 26 weeks showing stability of concentration (vc 1.6).
Considering the above, a shelf life of 36 months at room temperature is set for uracil powder 
in polypropylene bottles. The storage instruction will be to store the bottles below 30ºC.
2.2 Non-clinical pharmacology, pharmacokinetics and toxicology  
2.2.1 Test materials used in toxicity studies
Uracil powder.
2.2.2 Integrated assessment of the data package 
See CAS 66-22-8 [10].
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2.2.3 List of studies conducted & references
Table  3.6 LD
50
 values of uracil in different species [9]
Species Route of administration LD
50
Rat oral > 6 g / kg
Mouse oral > 8 g / kg
Mouse parenteral 1513 mg / kg
Dog oral > 5 g / kg
Rabbit oral > 10 g / kg
2.2.3.1 Safety data regarding long-term (chronic) administration of uracil
Uracil was administered to male and female dogs for 3 months and to male dogs for 12 
months at dose levels of 0, 210, 420, 840 and 1680 mg uracil per kg body weight per day by 
gavage. While there were minor differences seen in food consumption, water consumption 
and erythroid parameters between the 3-month and the 12-month studies, it was concluded 
that there were no adverse effects seen neither on these parameters nor on body weight, 
EKG, clinical laboratory studies and organ weights. Pathological observations did not show 
treatment-related effects [12].
2.2.4 GLP statement and bioanalytical methods 
The non-clinical pharmacology data have been extracted from the CAS database and from 
peer reviewed publications.
2.3 Clinical data 
2.3.1 Clinical pharmacology
Uracil is a non-toxic endogenous pyrimidine and essential part of the structure of RNA.
Uracil and 5-FU are chemically almost alike and both substances are substrates for DPD. 
Uracil is an endogenous pyrimidine involved in RNA synthesis and, accordingly, an excellent 














The pharmacokinetics of uracil after oral intake has been established in human volunteers 
and in patients with DPD deficiency in previous studies [5, 6].
There is no data available of pharmacokinetic parameters in special populations (i.e. age 
and gender, race, renal insufficiency, hepatic insufficiency).
2.3.3 Human exposure
In a Dutch study in 12 healthy volunteers, no adverse reaction was observed after oral 
ingestion of 500 mg/m2 and 1000 mg/m2 uracil [2, 3]. Oral administration of 6 mg/kg 13C 
labeled uracil in 255 American volunteers also did not reveal adverse reactions [1, 4].
2.4 Overall risk and benefit assessment
Uracil is an endogenous pyrimidine base and an essential part of the structure of RNA. 
The LD50 value of uracil is very high and ranges from 6–8 g/kg in rats, mice and rabbits 
[11]. Chronic oral administration of 1680 mg/kg uracil in dogs during 1 year appeared 
completely safe [12]. 
Uracil is commercially marketed in combination with tegafur in the pharmaceutical product 
UFT® (Merck). This product is registered for the treatment of colorectal cancer. The daily 
dose of uracil in this commercial formulation is 672 mg/m2. 
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ABSTRACT
Purpose: Dihydropyrimidine dehydrogenase (DPD) deficiency can lead to severe 
toxicity in patients treated with standard doses of 5-fluorouracil (5-FU). Oral 
uracil administration and subsequent measurement of uracil and dihydrouracil 
(DHU) plasma concentrations might detect patients with DPD deficiency. This 
study compares the pharmacokinetics (PK) of uracil and DHU after oral uracil 
administration in subjects with normal and deficient DPD status.
Methods: Five hundred milligrams of uracil per metre square was administered 
orally to 11 subjects with normal DPD status and to 10 subjects with reduced DPD 
activity. Repeated administration (n = 3) of this dose was performed in 4 subjects 
and 1,000 mg uracil/m2 was administered to 4 subjects to assess intra-individual 
variation and linearity of pharmacokinetics.
Results: In subjects with normal DPD status, 500 mg/m2 uracil resulted in uracil C
max
 
levels of 14.4 ± 4.7 mg/L at T
max
 = 30.0 ± 11.6 min and in DPD-deficient subjects, 
20.0 ± 4.5 mg/L at 31.5 ± 1.1. The uracil AUC
0>180
 was 31.2 ± 5.1 mg L/h in DPD-
deficient subjects which was significantly higher (p < 0.05) than in the subjects with 
normal DPD status (13.8 ± 3.9 mg L/h). Repeated uracil dosing showed reproducible 
uracil PK in subjects with normal DPD status and dose elevation of uracil suggested 
linear pharmacokinetics.
Conclusion: The PK of uracil differs significantly between subjects with a normal 
DPD activity and those with a deficient DPD status. The AUC and C
max
 of uracil 






















5-Fluorouracil and its prodrug capecitabine are commonly used chemotherapeutic drugs in 
the treatment of colorectal, breast and head and neck cancer. The intracellular metabolism 
of 5-FU is complex, requiring conversion into cytotoxic nucleotides. The main cytotoxic 
metabolite is 5-fluoro-2’-deoxyuridine 5’-monophosphate that inhibits thymidylate synthase 
[1]. However, only a small proportion of the administrated 5-FU dose is converted to cytotoxic 
metabolites. Within a few hours after parenteral administration, 70–90% of the 5-FU dose 
is metabolized into inactive metabolites. DPD is the initial, and rate-determining enzyme 
in the catabolism of 5-FU [2-5]. Patients with a partial or complete DPD deficiency have a 
strongly reduced capacity to degrade 5-FU [6, 7] or its oral prodrug capecitabine [8, 9]. As a 
consequence, treatment with 5-FU and/or capecitabine in patients with reduced DPD activity 
can cause severe or life-threatening toxicity such as neutropenia, diarrhea and mucositis 
[10]. It was initially estimated that in 3–5% of Caucasians the activity of DPD is strongly 
reduced due to (epi)genetic variations in the gene encoding DPD. However, this percentage 
can be disputed because the incidence of DPD deficiency depends on the method that is 
used to detect it [11] and the cutoff level chosen or determined to define DPD deficiency 
[12]. A recent study found DPD deficiency in 40% of the patients included using the uracil/
dihydrouracil ratio in plasma, an observation higher than the outcome expected with DPYD 
genetic polymorphism [13].
Several methods have been developed to detect patients with reduced DPD activity, such 
as genotyping [14], determination of DPD activity in peripheral blood mononuclear 
cells (PBMCs) [4, 10], phenotyping with a breath test using [2-13C] uracil [15-17], the 
administration of a 5-FU test dose [7, 18] and assessment of the endogenous uracil/DHU 
plasma ratio [19-27]. A major drawback of many of these methods is that they are costly 
and/or laborious or in the case of a 5-FU test dose potentially toxic, thus precluding the 
routine implementation in clinical practice for prospective screening of DPD deficiency. 
To achieve the most accurate and simple method to predict DPD deficiency prior to 5-FU- 
or capecitabine-based treatment, a combined testing strategy has been proposed [12, 21]. 
However, oral administration of an uracil test dose and subsequent measurement of uracil 
and its metabolite DHU in plasma might be a cheap, fast, and simple method for screening for 
DPD deficiency prior to 5-FU or capecitabine containing therapy, which can be used clinically. 
So far, only the pharmacokinetics of orally administered 13C-uracil has been reported using 
low doses of 50, 100, and 200 mg uracil. The major drawback of using low doses of uracil 
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concerns the lower chance of reaching adequate plasma concentrations. The use of higher 
uracil doses is expected to result in a more adequate discrimination between normal and 
deficient individuals due to a prolonged DPD enzyme saturation in DPD-deficient subjects 
compared with lower doses of uracil. Moreover, this situation may better reflect the DPD 
enzyme dynamics in the clinical situation when 5-FU doses of 1,000–2,000 mg are being 
used. From previous work with 5-FU, we estimated that a uracil plasma level of at least 10 
mg/l would be needed for proper discrimination between DPD-deficient and normal DPD 
subjects with high sensitivity and specificity [6]. 
The main objective of this study was to compare the pharmacokinetics of orally administered 
uracil between healthy volunteers with normal DPD activity and patients with DPD 
deficiency due to heterozygosity for a DPYD gene mutation. Secondary objectives involved 
the investigation of linearity of uracil pharmacokinetics at increased uracil dose and the 
intra- and interday variation in uracil pharmacokinetics.
MATERIALS AND METHODS 
Study subjects
Eleven subjects with a normal DPD status and ten DPD-deficient subjects, aged 18 years 
and older, participated in this study. The eleven subjects were all healthy volunteers and the 
ten DPD-deficient subjects were colorectal and breast cancer patients who suffered CTC 
grade III or IV side effects following a 5-FU or capecitabine containing drug schedules and 
had DPD activity < 5 nmol/mg protein/hr. DPD activity was measured in PBMCs, and 
the DPD status was considered normal or deficient when the DPD activity in PBMCs was 
> 5 nmol/mg protein/h, or < 5 nmol/mg protein/h respectively [11]. In all patients, DPD 
deficiency was confirmed by sequence analysis of DPYD showing heterozygosity for a 
pathological mutation. Heterozygosity for the c.1905 + 1G>A (IVS14 + 1G>A), c.2846A>T, 
c.1129 - 5923C>G, and the novel c.2579delA mutation was detected in 5, 2, 2, and 2 patients, 
respectively. One of the patients was heterozygous for both the c.1905 + 1G>A mutation 
and the c.1129 - 5923C>G mutation.
Prior to uracil administration, blood samples were taken to measure creatinine, alanine 
transaminase (ALAT), and gamma-glutamyl transpeptidase (gamma-GT) as markers for 





















The study was approved by the local Medical Ethics Committee of Diaconessen Hospital 
Meppel, the Netherlands. Informed consent was obtained from each subject.
Uracil administration
Uracil (Pharmorgana GmbH, Raubling/Rosenheim, Germany) was administered orally at 
a test dose of 500 mg/m2 body surface area, calculated by the DuBois and DuBois formula, 
after an overnight fast (last food intake > 8 h earlier). All subjects had to abstain food during 
2 hours after ingesting the uracil. All the test doses were administered between 08:00 a.m. 
and 09:00 a.m. to avoid circadian effects. The uracil powder was mixed with 100–200 ml 
tap water, and immediately after preparation, the suspension was ingested within a few 
minutes. In addition, repeated administration on subsequent days (n = 2 in 3 subjects and n 
= 1 in one subject) with 500 mg/m2 was performed in 4 volunteers to assess intra-individual 
variation and 1,000 mg uracil/m2 was administered to 4 volunteers to assess linearity of 
pharmacokinetics, respectively.
Collection of blood samples
A cannula was placed intravenously in one arm of each subject. Blood samples of 5 ml were 
collected in heparin-containing tubes. In an intensive sampling schedule, blood samples were 
collected just before and at t = 15, 30, 45, 60, 80, 100, 120, 150, 180, and 220 min (500 mg/
m2) or 240 min (1,000 mg/m2) after uracil intake. Samples were immediately placed on ice 
and subsequently centrifuged at 2,500 x g for 10 min at 4°C and stored at -20°C until analysis.
For the repeated uracil administration in the 4 subjects, blood samples were collected 
according to a limited sampling schedule. This schedule is based on results from an interim 
analysis on intensive schedule results from both volunteers and patients, in which t = 60 min 
and t = 120 min were selected as optimal sampling points for the limited sampling strategy.
DPD activity
The activity of DPD was determined in PBMCs using radiolabeled thymine followed by the 
separation of radiolabeled thymine from radiolabeled dihydrothymine using reversed-phase 
HPLC, as described before [28].
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Analytical method for uracil and dihydrouracil
Uracil and DHU plasma concentrations were measured by a validated HPLC method 
described by Maring et al. [29]. Calibration samples were prepared by spiking human 
heparinized plasma (Red Cross Blood Bank, Groningen, the Netherlands) with appropriate 
amounts of uracil and 5,6-DHU (Sigma Chemical Co, Zwijndrecht, the Netherlands). 
Uracil was quantified at 266 nm and DHU at 205 nm. The internal standard chlorouracil 
was quantified at both wavelengths. The limit of quantification in plasma was 0.004 mg/l 
for both uracil and DHU.
Pharmacokinetic and statistical analysis






 were calculated with PhoenixTM 
Winnonlin® Version 6 (Pharsight® Products, CA) using noncompartmental analysis. Mean 
plasma clearance was calculated with the formula Dose/AUC. Statistical analysis was 
performed by using SPSS version 16.0 (SPSS inc, Chicago, IL). Normality of data was tested 
by performing a Kolmogorov-Smirnov test.
To examine whether the uracil and DHU plasma concentrations and derived pharmacokinetic 
parameters differed between subjects with a normal DPD status and those with DPD 
deficiency, an unpaired Student’s t test was performed on data obtained from the 500 mg/
m2 dose. To investigate whether the distribution of gender in both groups differs between 
the DPD-deficient and normal individuals, chi-square statistic was used. One-way ANOVA 
analysis was performed on the uracil and DHU values measured in plasma at t = 60 and 
120 min in the four volunteers after repeated 500 mg/m2 doses to study the inter- and 
intrasubject variability.
RESULTS
The characteristics of the subjects included in this study are displayed in Table 4.1. No 
differences between the two groups were observed (p > 0.05) except for age, DPD activity, 
and disease status. 
The HPLC method that was used in this study revealed fully separated peaks for uracil and 





















The mean uracil and DHU plasma concentrations in the 11 subjects with normal DPD and 
in the 10 DPD deficient subjects following a uracil dose of 500 mg/m2 are depicted in Figure 






 and the mean Cl 
are displayed in Table 4.2.




 (n = 10) p value
Age (years) 38 ± 9 62 ± 12 < 0.001
Sex (male/female) 5/6 4/6 Chi square = 0.002
Weight (kg) 74 ± 10 76 ± 15 0.636
Height (cm) 177 ± 9 173 ± 5 0.154
PBMC DPD (nmol/mg/l) 7.2 ± 1.3 3.6 ± 0.8 < 0.001
Serum creatinine (μmol/l) 80 ± 10 78 ± 18 0.707
Serum ALT (U/l) 20 ± 8 25 ± 5 0.104
Serum gammaGT (U/l) 16 ± 6 39 ± 40 0.160
Values are displayed as mean ± SD.
Figure  4.1 Representative chromatogram obtained from a blood sample of a patient with normal 
DPD status at t = 60 min after oral intake of 1000 mg uracil. 
The chromatogram was recorded at 205 nm. The uracil and dihydrouracil concentrations were estimated as 
9.5 mg/L and 3.4 mg/L, respectively.
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 of uracil, AUC
0-180min
 and Cl of DHU did not differ between the two groups (p > 0.05). 
All the other displayed parameters differed significantly (p < 0.05). After reaching T
max
, the 
decline of uracil concentration in both groups followed zero-order kinetics, which sug-
gests that the DPD enzyme is fully saturated at the administered dose in both groups. In 
the subjects with normal DPD, after t = 100 min, the elimination changed gradually from 
zero order to first order, which resulted in an exponential decline. The same phenomenon 
occurred in DPD-deficient subjects, although at a later stage (after t = 150 min).
In subjects with normal DPD activity, uracil was completely eliminated within approximately 
180 min, whereas in DPD-deficient subjects the uracil plasma concentration was still 2.5 ± 
2.1 mg/l indicating that in DPD-deficient individuals the clearance of uracil was decreased. 
In addition, due to the reduced DPD activity, the reaction rate of the formation and the 
absolute amount of DHU were reduced in the group of DPD-deficient subjects. The uracil 
and DHU plasma concentrations measured in DPD-deficient subjects differed significantly 
(p < 0.05) as compared to the individuals with normal DPD except for uracil at t = 15 min 
(p = 0.071) and for DHU levels at t = 15, 120, 150 and 180 min (p = 0.149, p = 0.111, p = 
0.087, and p = 0.363, respectively).
Figure  4.2 Concentration-time profile of uracil and DHU in subjects with normal DPD (n = 11) and 
DPD-deficient subjects (n = 10) after oral intake of 500 mg/m2 uracil suspension. 
The results shown are the mean ± SD.
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Comparable uracil concentrations at t = 60 and 120 min were observed in subjects with 
normal DPD status who were tested multiple times. However, significant differences were 
observed for DHU levels at t = 60 and 120 min (p = 0.012 resp. p = 0.001).
Figure 4.3 shows the plasma concentrations of uracil and DHU after administration of 1,000 
mg uracil/m2 compared to 500 mg uracil/m2 in subjects with normal DPD status. The C
max
 
of both curves is reached after approximately 30 min (T
max
). Only after 45 min, the uracil 
levels differed significantly between both dosages. 
For DHU, the concentrations after ingestion of both doses differed not significantly the 
first 100 minutes, but after this point, the DHU concentrations measured in the group of 
1,000 mg/m2 were significantly higher. The Cmax values of uracil and DHU (Table 4.2) 
at 1,000 mg/m2 are, respectively 1.7 ± 0.3 and 1.5 ± 0.4 times higher compared with those 
after 500 mg/m2.
Figure  4.3 Concentration-time profile of uracil and DHU in subjects with normal DPD activity after 
oral administration of a dose of 500 mg/m2 (n = 11) and 1,000 mg/m2 (n = 4) uracil suspension. 






















In this study, it is shown that the pharmacokinetics of uracil after an oral uracil dose of 500 
mg/m2 was significantly different in subjects with DPD deficiency as compared to those 
with a normal DPD status suggesting that oral uracil administration may be useful as a test 
to determine patients with DPD deficiency. 
The patient characteristics of the two groups in which we studied uracil and DHU 
pharmacokinetics were comparable except for DPD status, age, and disease state. The 
subjects with normal DPD consisted of young healthy individuals, in contrast to the subjects 
with DPD deficiency, who all were colorectal and breast cancer patients. Aging involves 
progressive impairments in the functional reserve of multiple organs, which might also 
affect drug metabolism and pharmacokinetics [30]. With age, the liver mass and its perfusion 
decreases causing a diminished first pass effect of highly cleared drugs, and renal clearance 
of drugs is reduced by the loss of kidney function [31]. The liver contains a high amount of 
DPD, so increasing age might lead to reduced first pass effect and metabolism of uracil in 
the liver causing higher plasma concentrations in elderly compared to younger individuals. 
In addition, in cancer patients, metastases of the liver and steatosis caused by systemic 
chemotherapy [32] can reduce liver drug metabolism, which may also lead to changes in 
uracil metabolism. However, Maring et al. [33] described that extensive hepatic replacement 
due to liver metastases had no effect on 5-fluorouracil pharmacokinetics, indicating that 
the amount of DPD is probably not influenced by reduction in liver function. In addition, 
in our study population of DPD-deficient patients receiving systemic chemotherapy, no 
significant differences were observed in liver function or serum creatine compared with 
the group of healthy individuals. As a result of these findings, we consider it unlikely that 
the 2.6-fold decrease in clearance of uracil can be ascribed to differences in age or disease 
state between the two groups. The differences between the two uracil curves representing 
both the groups with and without DPD deficiency at 500 mg/m2 are caused by the amount 
of DPD available in deficient subjects, which is lower than in subjects with normal DPD 
activity causing reduces clearance of uracil. Mattison et al. [15] evaluated fixed doses of 
2-13C-uracil of 100, 200, and 300 mg as well as doses adjusted to body weight (1, 3, 6 and 
12 mg/kg). They demonstrated with their uracil breath test that an administered dose of 6 




 than single fixed doses of 100, 200, 
or 300 mg. The dose of 500 mg uracil/m2 used in our study is in range with the 2-13C-uracil 
dose of 12 mg/kg that was also used by Mattison et al. and with the commonly applied 
80
Dose finding and pharmacokineticsChapter 4
5-FU bolus doses of 400–600 mg/m2 in the treatment of colorectal and breast cancer [34-
37]. The gastrointestinal absorption of uracil is a pharmacokinetic first order process and 
the elimination follows a reversible and saturable Michaelis-Menten kinetics [17]. When 
DPD is saturated the elimination of uracil follows zero-order kinetics. The formation of 
DHU depends on the Km of DPD and the amount of uracil and enzyme present. When all 
the present DPD enzyme is saturated, the metabolism of uracil will depend on the absolute 
amount of DPD present and not on the amount of uracil, i.e., if the same dose of uracil is 
administered to two individuals with different enzyme levels, the individual with the highest 
amount of enzyme will have the highest “zero-order” reaction rate and the lowest C
max
 of 
both individuals. So, in order to discriminate between individuals with a normal DPD 
activity and those with a DPD-deficiency the uracil dose used needs to be high enough to 
saturate the DPD enzyme both in individuals with and without DPD-deficiency in order 
to achieve significant different plasma levels. For oral uracil to be used as a diagnostic test, 
the pharmacokinetics of uracil between patients with and without DPD deficiency has to be 
clearly discriminating. Mattison et al. [15] describe that the AUC following a dose of 6 mg/
kg 2-13C uracil is significantly different in subjects with normal DPD activity versus partial 
DPD-deficiency. This is in line with the results we found using a dose 500 mg/m2 uracil. 
For a broad clinical use, a diagnostic test has to be simple, cheap, sensitive, and specific. 
The uracil breath test is expensive because of the use of 2-13C uracil and breath bags, and 
the technique of IR spectrophotometry for analysis of exhaled samples is not available in 
every hospital. Our test might be more cost effective and might lead to quick test results 
since the price of 1 gram uracil is about 1 US$ and the HPLC equipment that is used for 
analysis is common in most hospitals for therapeutic drug monitoring purposes. If the 
HPLC equipment is not available at the testing site, the plasma samples have to be stable 
enough to be transported. Prior to this study, the stability of U and DHU in whole blood 
and plasma were determined. The results show that uracil in whole blood can be stored at 
4°C for up to 4 hours. The degradation of U and DHU in plasma was less than 2% during 24 
hour at room temperature. We therefore concluded that the stability in plasma is sufficient 
enough to perform the analytical extraction procedure without further precautions and 
that the plasma samples are suitable for transportation within 24 hours. As a result, our test 
can be incorporated broadly into common clinical practice. However, a disadvantage of the 
current setup of the test is the intensive blood sampling scheme that takes 4 hour to perform 
and makes it patient intense. The test has to be further optimized into a limited sampling 





















AUC, clearance, and C
max
 are less suitable for discriminating, but the uracil and/or DHU 
concentrations or U/DHU ratio at selected time points (e.g. 120 min after administration) 
might be. At this stage, it is unclear if monitoring DHU concentrations can be useful in 
a limited sampling strategy setting since we found only slightly different values in DHU 
pharmacokinetic parameters in both groups. This might be explained by the fact that the 
DHU levels are not only determined by the degradation of uracil by DPD but also by its 
volume of distribution and the subsequent hydrolysis of DHU into N-carbamyl-β-alanine 
by dihydropyrimidinase. We conclude that uracil administration at a single dose of 500 mg/
m2 leads to significant and reproducible differences in pharmacokinetics of uracil and DHU 





 might be useful to detect partial DPD deficiency. In addition, uracil doses above 
500 mg/m2 have no discriminating benefits but will only result in a right shift of the uracil 
and DHU concentration curve and unnecessary longer exposition to high uracil levels. The 
results presented here points toward a promising development of an oral uracil challenge as 
a diagnostic test for DPD deficiency. The sensitivity and specificity of this test are currently 
investigated in a larger population of cancer patients with and without DPD deficiency. 
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ABSTRACT
Purpose: Dihydropyrimidine Dehydrogenase (DPD) deficiency can lead to severe 
toxicity in patients treated with a standard dose of a fluoropyrimidine such as 
5-fluorouracil (5-FU) or capecitabine (CAP). Administration of oral uracil and 
subsequent measurement of uracil and dihydrouracil (DHU) plasma concentrati-
ons has been used to identify patients with DPD deficiency. Liver metastasis might 
influence systemic DPD activity. The aim of the study is to investigate the effect of 
metastatic disease on the pharmacokinetics of uracil and DHU after oral admini-
stration of uracil.
Methods: 500 mg/m2 uracil was administered orally to 12 subjects with stage II-III 
colorectal cancer (CRC) who were treated in the adjuvant setting and to 12 subjects 
with stage IV metastasized CRC, all treated with capecitabine containing therapy. 
All subjects had a normal DPD activity defined as >6 nmol/mg/h determined in 
peripheral blood mononuclear cells (PBMCs).
Results: The mean uracil clearance [CL 51.7 (SD 6.4) versus 46.7 (SD 13.0) l/h], Area 
under the curve [AUC
0-220min
 20.6 (SD 6.4) versus 21.0 (SD 5.7) h*mg/l], elimination 
half life [t
1/2
 21 (SD 7) vs 21 (SD 8) min], maximum concentration time [T
max
 27 (SD 
9) vs 25 (SD 9) min], Volume of distribution [V 26.58 (SD 10.11) vs 21.10 (SD 8.48) 
l] and the elimination constant [k
el
 2.01 (SD 0.56) vs 2.41 (SD 0.72) h-1] did not differ 
significantly (p > 0.05) non-metastatic CRC versus metastatic CRC.
Conclusions: Metastasis does not alter uracil pharmacokinetics and is similar in 
CRC patients with and without metastasis. Therefore, the uracil test dose could be 
used as a DPD phenotype test in both adjuvantly treated and metastatic CRC patients 














Capecitabine is an oral prodrug of 5-fluorouracil (5-FU). Both drugs are extensively used 
for the treatment of patients with colorectal, breast, gastric and head and neck cancer. 
Dihydropyrimidine dehydrogenase (DPD) is the rate-limiting enzyme in the catabolism 
of capecitabine and 5-FU, converting > 80% of an administered dose of 5-FU to inactive 
metabolites, a process mainly occurring in the liver. Patients with a partial or complete DPD 
deficiency have a strongly reduced capacity to degrade 5-FU, which may thus result in severe 
toxicity [1-5]. Several methods have been proposed to identify patients with reduced DPD 
activity [6]. Since uracil is a non-toxic structural analogue of 5-FU, the metabolism of uracil 
is similar to that of 5-FU and can therefore be used as a phenotype probe for DPD activity. 
Like fluoropyrimidines, uracil is metabolized initially by DPD and subsequently degraded 
by other enzymes into eventually beta-alanine [7] (Figure 5.1).
Figure  5.1 Catabolic pathway of uracil. 
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In a previous study we described the use of an oral uracil loading dose to assess the DPD 
status in healthy volunteers and in DPD-deficient CRC patients [8]. The purpose of the 
current study was to investigate whether or not the presence of metastases might influence 
the pharmacokinetics of orally administered uracil. The catabolism of 5-FU by DPD occurs 
mainly in the liver and contributes substantially to the metabolism of 5-FU [9, 10]. Liver 
metastases might alter uracil pharmacokinetics since in cancer patients, metastases in the 
liver and steatosis, caused by systemic chemotherapy, have shown to reduce drug metabolism 
[11]. Secondly, concomitant inflammatory responses have been observed during initiation, 
invasion, and metastasis of tumours. Components of cancer inflammation like chemokines, 
prostaglandins, and cytokines have shown to down-regulate cytochrome P450 enzyme 
activity [12]. Indeed, for CYP2C19, a discordant slow metabolizer phenotype compared to 
the predictive genotype was found in patients with advanced metastatic cancer [13]. For 
this reason it might be possible that the presence of a significant metastasis burden might 
alter DPD activity and uracil pharmacokinetics as well. Therefore, to further validate the 
oral uracil loading test, we performed a study in colorectal cancer patients treated with 
capecitabine to compare uracil pharmacokinetics in patients with metastatic disease and 
patients who were treated in the adjuvant setting without metastatic disease.
MATERIALS AND METHODS 
Calculation of sample size 
Based on the pharmacokinetic analysis of the data from 11 healthy volunteers enrolled a 
previous study [8] we calculated a mean uracil clearance of 50.6 l/hour with a variance of 
21%. We considered empirically that a difference in uracil clearance > 25% was clinically 
relevant. Based on this consideration, to achieve 80% power at a 0.05 significance level in 
order to detect a difference in uracil clearance in subjects with and without metastasizes, 
the calculated sample size is 24 (12 + 12).
Study subjects
Twelve subjects with metastasized CRC and 12 subjects with CRC in the adjuvant setting 
were included in this study. All subjects were treated with capecitabine containing therapy 













uracil pharmacokinetics caused by inactivating DPYD mutations. The value of > 6 nmol/
mg/h is a threshold level to distinguish individuals with and without DPD deficiency [14]. 
All subjects were aged > 18 years and had adequate renal and liver function. Three hospitals 
in the Netherlands participated in this study that was approved by the Medical Ethics 
Committee BEBO in Assen, The Netherlands. Informed consent was obtained from all 
individual participants included in the study. Prior to uracil administration, blood samples 
were obtained to measure creatinine clearance, alanine transaminase (ALAT) and gamma-
glutamyl transpeptidase (gamma-GT) as markers for renal function and liver damage.
Uracil administration
Uracil (Pharma Waldhof GmbH, Düsseldorf, Germany) was administered orally at a test 
dose of 500 mg/m2 body surface area, calculated by the Dubois and Dubois formula, after 
an overnight fast (last food intake > 8 h earlier). All subjects had to abstain from food during 
2 hours after oral administration of uracil. Administration took place at least 48 hours after 
the last administration of capecitabine. All the test doses were administered between 08:00 
AM and 09:00 AM to avoid circadian effects. The uracil powder was mixed with 100–200 
mL of tap water and immediately after preparation the suspension was ingested within a 
few minutes. 
Collection of blood samples
Blood samples were obtained at t = 0, 15, 30, 45, 60, 80, 100, 120, 150, 180 and 220 min from 
an intravenous indwelling catheter. 
Samples were immediately placed on ice and subsequently centrifuged at 2,500 x g for 10 
min. The plasma was stored at -20°C until analysis.
DPD activity
The activity of DPD was determined in PBMCs using radiolabeled thymine followed by 
separation of radiolabeled thymine from radiolabeled dihydrothymine using reversed-phase 
HPLC and online detection of radioactivity, as described before [15].
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Analytical method for uracil and dihydrouracil
Uracil and DHU plasma concentrations were measured by a validated HPLC method 
described by Maring et al. [16]. Calibration samples were prepared by spiking human 
heparinised plasma obtained from volunteers with appropriate amounts of uracil and 5,6-
DHU (Sigma Chemical Co, Zwijndrecht, The Netherlands). Uracil was quantified at 266 nm 
and DHU at 205 nm. The internal standard chlorouracil was quantified at both wavelengths. 
Pharmacokinetic and statistical analysis
The pharmacokinetic parameters area under the curve (AUC
0-220min
), uracil clearance (Cl), 
maximum uracil concentration (C
max
) and maximum concentration Time (T
max
) were 
calculated with ‘KINFIT module’ of MwPharm version 3.50 (Mediware, Groningen, the 
Netherlands)®. KINFIT is a Bayesian curve fitting module in which we used a one compart-
ment model. The AUC was calculated by a logarithmic trapezoidal rule. Statistical analysis 
was performed by using SPSS version 19.0 (SPSS inc, Chicago, IL). To examine whether the 
uracil and DHU plasma concentrations and derived pharmacokinetic parameters differed 
between the two study groups, an independent-samples Student’s t-test was performed. 
Levene’s test for equality was used to determine if the variance of each pharmacokinetic 
parameter was equal.
RESULTS
Table 5.1 displays the characteristics of the patients included in this study. In the metastasized 
group all patients had liver metastasis. Length, weight, age, BSA, leukocyte count, renal- 
and liver function were inventoried in all patients and did not differ significantly (p > 
0.05) between the two study groups. DPD activity was equally distributed between the 
two groups [9.5 (SD 2.9) and 10.3 (SD 1.8) nmol/mg/h respectively]. The patients in the 
adjuvant and metastatic group were using capecitabine as monotherapy (n = 12), combined 
with oxaliplatin (n = 7) or combined with oxaliplatin and bevacizumab (n = 5) for treatment 
of CRC. Capecitabine and bevacizumab was only used in the metastatic group. Mean age 
of subjects adjuvantly treated for CRC was 63 (SD 10 years) and 69 (SD 6 years) for those 
with metastatic disease. Mean Body Surface Area (BSA) did not differ between the patients 













Table 5.2 displays the pharmacokinetic parameters of the two study groups. Clearance 
of uracil was lower in the group with metastatic disease [46.7 (SD 5.7) l/h] compared to 
clearance in adjuvantly treated patients [51.7 (SD 11.7) l/h], but the difference was not 
statistically significant (p = 0.327). Figure 5.2 shows the concentration-time curves for uracil 
and DHU in both study groups. The mean exposure to uracil was not different (p = 0.889) 
between the two groups [AUC
0-220min
 20.6 (SD 6.4) h*mg/l for adjuvantly treated patients 
and for metastatic patients AUC
0-220min
 21.0 (SD 5.7) h*mg/l]. The time to reach T
max
 did not 
differ but the maximum concentration of uracil was significantly different between the two 
groups with 19.9 mg/l (SD 4.0) in the adjuvantly treated group and 25.8 mg/l (SD 5.7) in the 
Table  5.1 Patient characteristics of the study population with standard deviation between brackets
Baseline characteristic Adjuvant Metastasis
DPD activity (nmol/mg/l) 9.5 (2.9)  10.3 (1.8)
Creatinine (μmol/l) 76.6 (15.8)  79.8 (18.1)
ALAT (U/l) 27.4 (8.1)  22.7 (11.6)
GammaGT (U/l) 39.8 (11.5)  52.7 (39.3)
Leukocytes (mmol/l) 4.9 (1.6)  5.9 (1.8)
Weight (kg) 82 (13)  84 (11)
Length (cm) 174 (7)  177 (10)
BSA (m2) 1.97 (0.20)  2.01 (0.19)
Age (y) 63 (10) 69 (6) 
Adjuvant, adjuvantly treated CRC patients; metastasis, study group with metastatic CRC; ALAT, Alanine Amino 
Transferase; GammaGT, Gamma-glutamyltransferase; BSA, Body Surface Area.
Table  5.2 Pharmacokinetic parameters of the two study groups with standard deviation between 
brackets
Pharmacokinetic parameter  Adjuvant Metastasis p value
AUC
0-220min
 (h mg/l) 20.6 (6.4) 21.0 (5.7) 0.889
CL (l/h) 51.7 (11.7) 46.7 (13.0) 0.327
T
half
 (min) 21 (7) 21 (8) 0.927
T
max
 (min) 27 (9) 25 (9) 0.600
C
max
 (mg/l) 19.9 (4.0) 25.8 (5.7) 0.008
V (l) 26.58 (10.11) 21.10 (8.48) 0.164
k
el 
(h-1) 2.01 (0.56) 2.41 (0.72) 0.136
Adjuvant, adjuvantly treated CRC patients; metastasis, study group with metastatic CRC; AUC, Area Under the 
Curve; T
half
, elimination half time; T
max
, time point of maximum concentration; C
max
, maximum concentration; 
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group with metastatic disease (p = 0.008). Also, the half-life of uracil did not differ and was 
21 minutes for both groups, as was the case for the volume of distribution and elimination. 
No adverse events related to uracil administration of uracil were identified in the study.
DISCUSSION
This is the first study investigating the potential effect of metastatic disease on uracil 
pharmacokinetics in CRC patients with a normal DPD activity. Our results show that 
metastasis has no effect on uracil pharmacokinetics. Hypothetically, the extent of metastatic 
disease might influence DPD activity and uracil pharmacokinetics. In our study the patients 
with metastatic disease all had a good health performance. Liver enzymes were normal in 
both study groups and no patients with extreme cachexia have been identified. Therefore, 
we cannot fully exclude that the presence of cachexia, commonly seen in metastatic disease, 
might influence uracil PK. 
This study did not reveal a difference in uracil pharmacokinetics between patients adjuvantly 




































observed for the adjuvantly treated group is in line with C
max
 observed in a previous study 
[9]. C
max
 is determined by dose, absorption/degradation rate of a drug and volume of 
distribution, which are considered to be equal between the two study groups. Based on the 
pharmacokinetic profile of capecitabine and the fact that both groups were treated with 
capecitabine, we find it not likely that capecitabine might tribute to this observation. In the 
metastatic group however, patients were treated with bevacizumab. The test was performed 
more than 14 days after bevacizumab administration, but since the long elimination half time 
of approximately 20 days of this drug, we cannot exclude the possibility that bevacizumab or 





 however does not play a role of interest if the test is used to discriminate between 
DPD-deficient individuals and individuals with a normal DPD status. In this context we 
focused on uracil and DHU levels at t = 120 min.
In this study, we did not perform a pharmacokinetic analysis of dihydrouracil. Dihydrouracil 
has its own unique elimination pathway (Figure 5.1). Dihydropyrimidinase deficiency is 
very rare and since its effect on the toxicity of fluoropyrimidines is not known, we did not 
investigate the pharmacokinetics off dihydrouracil.  
We enrolled only patients with a normal DPD activity in the study. This study setup was 
chosen to exclude the effect of DPYD polymorphisms that have a large effect on uracil 
pharmacokinetics [17]. Such as large decrease of DPD enzyme activity caused by DPD 
polymorphisms would have excluded the detection of a smaller effect of metastatic disease 
on uracil PK. In this study, concomitant use of DPD-inhibiting medication such as cimetidine 
was not allowed and could therefore not have confounded the results. 
The orally administered uracil did not result in any adverse events in our patients and can 
be used safely. Orally administered uracil 500 mg/m2 is considered to saturate DPD fully 
during the period that plasma concentration levels are above the Michaelis constant [8]. 
Because of this, differences in DPD activity between individuals will become more profoundly 
clear than the determination of physiological levels of uracil/DHU ratios, which show 
high variation between individuals [5, 18-21]. Our oral uracil loading test is useful to be 
introduced into clinical practice. However, the test can be further optimized with a limited 
sample strategy in combination with the dried blood spot method for sample selection 
and patient convenience. In conclusion, in patients with a normal DPD activity, with the 
exception of C
max
 we found no evidence for different uracil pharmacokinetics in patients 
with metastatic CRC as compared to CRC patients treated adjuvantly. Since C
max
 is not used 
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as a discriminating parameter, orally administered uracil could therefore be used as a DPD 
phenotype test in both adjuvantly treated and metastatic CRC patients using the same cut 
off criteria. The results of this study look very promising to use the oral uracil loading dose 
as a easy and robust test to evaluate DPD activity in a clinical setting. 
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AbstrAct
Aim(s): Dihydropyrimidine dehydrogenase (DPD) deficiency can lead to severe 
toxicity following 5FU or capecitabine (CAP) treatment. Uracil (U) can be used as 
a probe to determine the systemic DPD activity. This study was performed to assess 
the sensitivity and specificity of an U loading dose for detecting DPD deficiency.
Methods: Cancer patients with Common Toxicity Score (CTC) grade III or IV 
toxicity after the first or second cycle of 5-FU or capecitabine treatment were asked to 
participate. Based on DPD activity in PBMCs, patients were divided in 2 groups: DPD 
activity in PBMCs < 5 nmol mg-1*h-1 (deficient group) and ≥ 5 nmol mg-1*h-1. U 500 
mg m-2 was administered orally and plasma concentrations of U and dihydrouracil 
(DHU) in plasma were determined. In the deficient group, PCR amplification of 
all 23 coding exons and flanking intronic regions of DPYD was performed. An U 
pharmacokinetic model was developed and used to determine Vmax of the DPD 
enzyme of each patient. Sensitivity and specificity of Vmax, U concentration and the 
U/DHU concentration ratio were determined.
Results: 47 patients were included (19 DPD deficient, 28 DPD normal). Of the 
pharmacokinetic parameters investigated, a sensitivity and specificity of 80% and 
98% respectively was obtained for the U/DHU ratio at t = 120 min.
Conclusions: The high sensitivity of the U/DHU ratio at t = 120 min for detecting 
DPD deficiency as defined by DPD activity in PBMCs, show that the oral U loading 








5-Fluorouracil (5-FU) is extensively metabolized by dihydropyrimidine dehydrogenase 
(DPD) into fluorodihydrouracil (FDHU) [1-4]. Reduced activity of DPD will result in altered 
5-FU pharmacokinetics (PK) [5-7] and the increased exposure to 5FU can cause severe side 
effects [8]. Pre-emptive testing followed by dose reduction for patients with DPD deficiency 
might prevent these severe side effects [7]. Despite the fact that several tests are available to 
screen for DPD deficiency, only a few are implemented on a broad scale in a pre-emptive 
setting [9]. Previously, we showed that administration of an oral loading dose of U allows 
the identification of patients with normal DPD activity and DPD deficient patients [10]. 
However, the intensive blood sampling scheme that was used previously is a major drawback 
for a pre-emptive setting [10]. Quantitative compartmental modeling has proven to be a 
sensitive tool in describing the mechanisms involved in PK [7]. The object of this study was 
to develop a limited sampling strategy, to detect decreased U elimination in patients with a 
DPD deficiency and to perform a more in-depth quantitative compartmental pharmacokinetic 
analysis of U plasma concentrations.
MAterIAls And Methods 
Patients and study design
Patients were included in 10 hospitals in The Netherlands between August 2006 and 
December 2013. The study population consisted of cancer patients who suffered from CTC 
grade III or IV toxicity after the first or second cycle of treatment schedules containing 
5-FU or capecitabine. Since the incidence of DPD deficiency is relatively (3–5%) low in the 
Caucasian population [2], only patients with toxicity were included in order to increase the 
likelihood to find DPD deficient patients. DPD activity in PBMCs [11] was determined and 
patients were divided in 2 groups: patients with DPD activity in PBMCs < 5 nmol mg-1*h-1 
were considered deficient (deficient group) while patients with activity ≥ 5 nmol mg-1*h-1 
were classified as normal with respect to DPD status (normal group, mean ± SD controls: 
9.9 ± 2.8 nmol mg-1*h-1). Coefficient of variation (CV) and limit of detection (LOD) of this 
assay were previously described [11]. No discrimination was made between tumour type 
or adjuvant treatment versus metastatic disease. The study flow diagram is displayed in 
Figure 6.1.
102
Limited sampling strategyChapter 6
Figure  6.1 Flowchart of the study design. 
5-FU, 5-fluorouracil; DPD, dihydropyrimidine dehydrogenase; PCR, polymerase chain reaction.
Treatment with a 5-FU or 
capecitabine containing 
regimen
Let the patient recover
Collect blood sample for 
DPD activity
DPD activity < 5 nmol/
mg/hr (n = 19)
DPD activity > 5 nmol/
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In all participants, U 500 mg m-2 as a loading dose was administered orally followed by blood 
sampling as described before by using 2 different sampling schemes [10]. The U test dose 
was administered in the morning around 08:00 after an overnight fast to minimize variance 
caused by possible circadian effects off DPD activity and food intake. Plasma concentrations 
following the loading dose of U and its metabolite dihydrouracil (DHU) were determined 
by high performance liquid chromatography (HPLC) [12]. CV of U were 4.8% (4 mg l-1) 
and 3.7% (18 mg l-1), and 8.8% (1 mg l-1) and 5.7% (3 mg l-1) for DHU. LOD is 0.060 mg l-1 
for both U and DHU. In the deficient group, genetic analysis of DPYD was performed by 
PCR amplification of all 23 coding exons and flanking intronic regions followed by sequence 
analysis, essentially as described before [8]. In all patients, prior before the U loading dose 
was administered, endogenous concentrations of U, thymine, DHU, dihydrothymine, 
N-carbamyl-ß-alanine and N-carbamyl-ß-aminoisobutyric acid in plasma were determined 
using reversed-phase HPLC combined with electrospray tandem mass spectrometry [13, 
14]. CV and LOD of this method were described before [13]. Values of creatinine, alanine 
transaminase (ALAT), gamma-glutamyl transpeptidase (Gamma-GT) and white blood cell 
count measured before the occurrence of fluoropyrimidine related toxicity of all subjects 
were collected. Toxicity data was collected and scored by the local investigator of each 
participating hospital according to the Common Toxicity Score (CTC) version 3. The CTC 
was scored for the typical fluoropyrimidine side effects diarrhea, stomatitis, neutropenia 
and hand-foot syndrome. The cumulative CTC score of each individual was obtained by 
calculating the sum of all CTC ratings. The mean cumulative CTC score of both study 
groups was used to compare the toxicity burden between both groups. The study protocol 
was approved by the Ethics Review Committee of the Martini Hospital Groningen in the 
Netherlands and all patients gave written informed consent.
Pharmacokinetic analysis
All patients received orally 500 mg m-2 U after which blood was taken prior after intake. A 
full sampling scheme (FSS) in which blood samples were collected at 0, 15, 30, 45, 60, 80, 
100, 120, 150, 180 and 240 minutes was applied in the first 10 patients of both study groups. 
A limited sampling scheme (LSS) in which blood was taken prior to the intake and at 60 
and 120 minutes was applied to all other subjects in both study groups. The time points of 
the LSS were determined as the optimal LSS points based on results of an interim analysis 
as previously reported [10]. The pharmacokinetic parameters that were investigated were 
the U concentration at t = 120 minutes, the U/DHU ratio at t = 120 min and the Vmax value 
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derived from a pharmacokinetic U model. To calculate the Vmax of both study groups, the 
following approach was used: based on U and DHU concentrations measured in the blood 
samples of the FSS of both study groups, a population one-compartment model (EURMIX 
model) with Michaelis-Menten elimination PK was developed with the ‘KINPOP module’ 
of MwPharm version 3.50 (Mediware, Groningen, the Netherlands) [15]. The elimination 
parameters were: Michaelis-Menten constant (KM), Vmax, the aparent volume of the central 
or plasma compartment in a one compartment model (V1) and absorption constant (ka). 
Pharmacokinetic parameters were assumed to be distributed log-normally. Since no data 
is available with respect to the oral bioavailability of U, we assumed that 100% of the 
administered dose was absorbed from the gastrointestinal tract since the gastrointestinal 
absorption of U is a fast pharmacokinetic first order process [16]. 
The same principle was used to develop population models for the DPD deficient (EURDEF 
model) and DPD normal (EURNOR model) study groups. The EURMIX model was used 
to calculate the Vmax of all individual subjects based on the LSS, with the use of an iterative 
two stage Bayesian (ITBS) procedure [15, 17]. To establish the performance of the LSS, the 
FSS data were used for an explorative internal validation. Using the FSS data, Vmax,FSS values 
were calculated with the EURMIX model. Subsequently in the same dataset Vmax,LSS values 
were calculated with the EURMIX model using only U and DHU data of the t = 60 and 120 
minutes samples. Both Vmax,FSS and Vmax,LSS were compared by correlation analysis and the 
performance of the LSS was considered valid if the mean prediction error was < 5% and the 
root mean square error (RMSE) was < 10%.
statistical analysis
Normal distribution of data was tested by performing the Shapiro-Wilk test. Comparison of 
parameters between the two study groups was performed by using the two-sample Student’s 
t-test and Chi square analysis. Receiver operating characteristic (ROC)-curves were used 
to determine the cut-off levels bases of sensitivity (true positive rate) and specificity (true 
negative rate). The level of significance was set at p ≤ 0.05. Analysis was performed by using 









In total 47 cancer patients aged > 18 year were included, 19 in the DPD deficient group and 
28 in the DPD normal group based upon DPD enzyme measurement in PBMCs. Because 
several patients were included simultaneously in different hospitals after starting the study, 
the FSS was applied to more than 10 patients in each study group. In the deficient and 
normal group the FSS was performed in 14 resp 12 patients. The patient characteristics are 
displayed in Table 6.1.
Of all characteristics, only the DPD activity in PBMCs differed significantly between the two 
groups (p < 0.05). Weight, length, age, liver- and renal function did not differ significantly. 
From measurement of the endogenous pyrimdine metabolites, we found that none of the 
metabolite levels or the calculated metabolite ratios was significantly different between 
the two study groups (p > 0.05). In the DPD deficient group all patients had at least one 
pathogenic DPYD variant: c.1129-5923C>G (n = 4), c.2579delA (n = 2), c.2846A>T (n = 3), 
c.1905+1G>A (n = 10), c.1679T>G (n = 1). No difference in U PK was observed between 
the different variants.
PK analysis of u
Table 6.2 displays the pharmacokinetic parameters of the EURDEF, EURNOR and EURMIX 
models. There are clear differences in the Vmax values of the different models and is lowest 
in the DPD deficient pharmacokinetic model (mean ± SD 494 ± 133 mg*h-1 1.85 m-2) and 
highest in the population with normal DPD activity (mean ± SD 837 ± 130 mg*h-1 1.85 m-2).
lss
Figure 6.2 displays the correlation between the Vmax calculated with the EURMIX model for 
the LSS and full sampling for the subjects who underwent the FSS. The root mean square 
error and the mean prediction error were < 7.3% and < 1.8%, respectively showing that 
Vmax values calculated from the data of the limited sampling schedule are comparable to 
those calculated from the intensive sampling schedule. The Vmax values calculated with the 
EURMIX model based on the LSS time points in all subjects differed significantly between 
the two study groups (p < 0.001) as is shown in Figure 6.3. 
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table  6.1 Patient characteristics
Parameter ID Mean SD SEM p-value
Weight (kg) DPD normal 70 12 2.187 0.114
DPD deficient 76 14 3.176
Length (m) DPD normal 170 9 1.697 0.835
DPD deficient 170 8 1.812
Age (year) DPD normal 63 11 1.997 0.592
DPD deficient 62 10 2.408
Kreatinine (µmol l-1) DPD normal 74 19 3.654 0.277
DPD deficient 81 20 4.627
ALAT (U l-1) DPD normal 28 20 4.268 0.22
DPD deficient 22 6 1.572
GammaGT (U l-1) DPD normal 107 131 29.265 0.057
DPD deficient 39 31 7.964
WBC (106 l-1) DPD normal 6.0 1.8 0.3761 0.596
DPD deficient 6.4 2.4 0.5878
DPDact in PBMCs (nmol mg-1*h-1) DPD normal 9.9 3.5 0.6642 < 0.001
DPD deficient 3.8 1.5 0.3426
Dhu (µmol l-1) DPD normal 0.93 0.42 0.09 0.522
DPD deficient 0.85 0.33 0.08
Dht (µmol l-1) DPD normal 0.93 0.55 0.11 0.250
DPD deficient 0.77 0.21 0.05
NCbala (µmol l-1) DPD normal 0.19 0.10 0.02 0.284
DPD deficient 0.15 0.10 0.02
NCbaib (µmol l-1) DPD normal 0.13 0.10 0.02 0.060
DPD deficient 0.08 0.03 0.01
Uracil (µmol l-1) DPD normal 0.25 0.10 0.02 0.205
DPD deficient 0.29 0.10 0.02
Thy (µmol l-1) DPD normal 0.05 0.02 0.00 0.995
DPD deficient 0.05 0.03 0.01
Uracil/DHU+NC-bala DPD normal 0.28 0.15 0.03 0.486
DPD deficient 0.32 0.14 0.03
Thy/DHT+NC-baib DPD normal 0.06 0.04 0.01 0.949
DPD deficient 0.06 0.04 0.01
U/NC-bala DPD normal 1.66 1.24 0.2491 0.125
DPD deficient 2.31 1.32 0.3314
Thy/NC-baib DPD normal 0.56 0.39 0.0789 0.265
DPD deficient 0.77 0.77 0.1921
WBC, white blood cells; Thy, thymine; DHU, dihydrouracil; U, uracil; Dht, dihydrothymine; NC-bala, N-carbamyl-








There was no statistical difference observed in fluoropyrimidine specific cumulative toxicity, 
i.e. diarrhea, stomatitis, neutropenia and hand-foot, between the DPD normal and DPD 
deficient group (p = 0.495). Diarrhea was the most reported side effects in both study groups. 
Chi square analysis revealed no significant difference in reported numbers of CTC grade I, 
II, III or IV toxicity and toxic side effects diarrhea, stomatitis, neutropenia and hand-foot 
syndrome between the two study groups (all p-values > 0.05).
table  6.2 Population pharmacokinetic parameters ± standard deviation estimated in dihydropyrimidine-
dehydrogenase deficient subjects (eurdeF model). subjects with normal dPd activity (eurnor model), 
and all subjects (eurMIX).
Km (mg l-1) Vmax (mg h
-1 1.85 m-2) ka po (h-1) V(l)
EURDEF 5.99 ± 4.17 494 ± 133 5.61 ± 7.16 0.57 ± 0.09
EURNOR 7.69 ± 1.38 837 ± 130 4.65 ± 3.33 0.51 ± 0.14
EURMIX 7.10 ± 3.33 641 ± 178 5.13 ± 4.87 0.55 ± 0.12
Km, Michealis-Menten constant; Vmax, maximum enzymatic conversion capacity; ka, absorption constant; V, 
apparent volume of drug distribution; po, per oral.
Figure  6.2 comparison of maximum enzymatic conversion capacity (Vmax mg h
-1*1.85 m-2) values 
calculated for the limited sampling and intensive sampling strategy with the eurMIX model. 
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roc curves
The cut-off levels for Vmax,LSS value, U/DHUt=120min ratio and Ut=120min concentrations were esti-
mated by ROC analysis (Figure 6.4). The data are displayed in Table 6.3. For the U/DHUt=120min 
ratio, a cutoff level of 2.4 will result in a sensitivity of 80% and specificity of 98% with a 
Figure  6.3 Vmax,lss (mg h
-1*1.85 m-2) values calculated using the limited sampling strategy model in 
normal dihydropyrimdine dehydrogenase (dPd) and dPd deficient patients. 
The top line, bottom line and middle line through the box correspond to the 75th, 50th, and 25th percentiles, 
respectively. The grey circle represents an outlier.
 
table  6.3 sensitivity, specificity and cut-off levels for maximum enzymatic conversion capacity for the 
limited sampling strategy (Vmax,lss), uracil/dihydrouracil ratio at t = 120 min (u/dhut=120min) and ut=120min 
concentration derived from roc curves
Test parameter Cutt-off level Sensitivity (%) Specificity (%) npv% ppv%
Vmax (mg hr
-1 *1.85 m-2) 667 80 78 99 16
Uracil DHU-1120min ratio 2.4 80 98 99 67
Uracil120 min (mg l
-1) 6.4 80 96 99 51































Figure  6.4 reciever operating characteristic (roc) curves for the uracil/dihydrouracil (u/dhu) ratio 
at t = 120 min, u concentration at t = 120 min and maximum enzymatic conversion capacity for the 
limited sampling strategy (Vmax,lss). 
The areas under the curves are 0.981; 0.957 and 0.874 for U/DHU at t = 120 min, U concentration at t = 120 



















ROC curve U conc t = 120 min
ROC curve U/DHU ratio t = 120 min
ROC curve Vmax,LSS
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positive predictive value of 67% and a negative predictive value of 99% to discriminate bet-
ween subjects with normal DPD activity and DPD deficient subjects. The cut-off levels of 
Vmax,LSS and Ut=120min showed lower specificity values when a sensitivity of 80% was chosen.
dIscussIon
In this study we developed a limited sampling model as a screening tool for DPD deficiency. 
Several parameters were evaluated with respect to sensitivity and specificity of DPD 
deficiency. Based on our experience on the field of 5-FU pharmacokinetic modeling [7] we 
investigated the potential value of Vmax to interpretate U pharmacokinetics. The PK models for 
a DPD deficient population and DPD normal population revealed significant differences in 
Vmax which is in the deficient population 42% lower compared to a normal population. Despite 
this significant difference, there is an overlap in Vmax because of the Gaussion distribution 
within the population. This result is in line with the results of pharmacokinetic analysis of 
5-FU plasma levels performed by van Kuilenburg et al [7], and also with the fact that the 
mean DPD activity in patients heterozygous for a DPYD mutation is 48% of that observed 
in controls [7]. We validated the Vmax,LSS model by using LSS en FSS data employed in one 
population. This can be problematic because validation results and sensitivity/specificity 
values might be falsely influenced and elevated by this approach. Our validation involved 
only an explorative internal validation of the model in which each case is its own control. We 
realize that this should be followed by an external validation in which a different population 
should be used. There are two reasons that we did not perform this external validation. First, 
despite the fact that sensitivity and specificity results might be falsely influenced and elevated, 
the sensitivity and specificity are still lower compared to the U/DHU ratio. We consider it 
unlikely that external validation will result in higher sensitivity and specificity compared to 
U/DHU ratio. Secondly, to work with Vmax and PK modeling, highly sophisticated software 
and knowledge of PK are necessary and these are not present in every hospital. This latter 
issue means that Vmax is not a suitable candidate for use in a test performed in a prospective 
setting. The results of this study show that the U/DHUt=120 min ratio is superior to Vmax as a 
discriminating parameter. A possible explanation for this is that the calculated Vmax value is 
based on U plasma data only. DHU plasma data are not included in the model. Compared 
to a previous developed 5FU iv PK model [7], the oral U PK model is more complex due 
to interindividual variability in bioavailability. Theoretically, the prediction of Vmax might 







The arrangement of the two study groups was based on the DPD activity in PBMCs. This 
enzymatic assay is influenced by factors such as lymphocyte, granulocyte and monocyte 
composition in peripheral blood and protein concentration. In this study however, we took 
into account all the potential pitfalls of this assay as identified before [11]. The results of 
the analysis in the present study did not identify any outliners in the study population. The 
power of the DPD activity assay in this study was further demonstrated by the fact that in 
the deficient group, pathogenic DPYD variants were detected in all subjects. 
The study population concisted of patients with a history of severe toxicity while treated 
with 5-FU of capecitabine in order to enrich to DPD deficiency. The results can therefore 
only be interpreted for this population. Theoretically it is highly possible that patients in the 
DPD normal group might have varying degrees of DPD deficiency. This makes it difficult 
to apply the results to the general cancer population that also consists of patients without 
toxicity. Further research is needed in order to determine if the results of this study also apply 
to the general population. In this study we defined patients with a DPD activity in PBMCs 
< 5 nmol mg-1*h-1 as DPD deficient. This migh lead to the discussion if a different value for 
DPD activity will result in different sensitivity and specificity. In order to investigate this, 
we performed a sensitivity analysis in which we calculated the sensitivity and specificity by 
ROC analysis based on a DPD activity cut off level of < 5.5 and < 6.0 nmol mg-1*h-1 which 
resulted in a specificity of 92.3% and 90.9% respectively when sensitivity is 80%. This shows 
that the cut-off chosen in the present study will have the smallest percentage of false positive 
test results.
The LSS strategy is an important improvement compared to the intensive sampling scheme 
that was used previously [9] and is more convenient for the patient. As the prevalence of a 
partial DPD deficiency in the general population is at least 3–5% [2], a prospective test in 
order to detect deficiency has to be applied to a large number of patients to find those few 
individuals with a low DPD activity. We decided to choose a cut-off level for our test whereby 
the number of individuals with true positive results favours the number of individuals with 
false positive results. In a population of 1000 persons and an incidence of 5%, a sensitivity of 
80% and a specificity of 98%, there will be 40 individuals with a true positive test result and 
19 with a false positive test results, leading to a positive predictive value of 67%. As positive 
test cases are at risk of developing severe toxicity when fully dosed, we recommend that a 
dose reduction of 50% should at least be considered in line with the recommendations of 
the Royal Dutch Association for the Advancement of Pharmacy for DPYD genotyping [18]. 
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After an initial dose reduction and no toxicity, a dose escalation strategy could be followed 
in small steps based on clinical tolerability observed after each treatment cycle. 
How do the results of this study compare with other strategies that are developed to detect 
DPD deficiency or prevent fluoropyrimidine related toxicity? There have been several 
genotyping studies in which sensitivity and specificity were established [19, 20]. It is difficult 
to compare our study results with these results, since these studies used different endpoints 
to the DPD activity that was used in our study. Only a head to head study would enable a 
fair comparison to be made between a genotyping and phenotyping strategy possible. 
Compared to genotyping, an advantage of a phenotyping test strategies is that genetic 
variants outside the coding region of DPYD resulting in either a systemically altered DPD 
activity or altered 5-FU metabolism will be detected with these approaches. The incidence 
of these genetic variants however is very low as was proved by the fact that all subjects in 
the deficient group had variants inside the coding region of DPYD. 
Among the included subjects, we identified one individual with a normal DPD activity in 
PBMCs of 8.3 nmol mg-1*h-1 who had highly elevated U and DHU levels comparable to 
the other DPD deficient subjects. Mutation analysis of DPYD in this individual revealed 
the presence of the pathogenic c.1905+1G>A variant. Heterozygosity for this mutation, in 
combination with a low but normal DPD activity has been previously described before by 
van Kuilenburg et al [21]. Another individual included in the present study had a very low 
DPD activity in PBMCs of 1.0 nmol mg-1*h-1 but the oral loading dose test results showed 
U and DHU considerably lower than the other DPD deficient subjects. Additional sequence 
analysis of DPYD in this case showed that there were no DPYD variants present. This 
observation was previously described by others investigators [8]. These two cases show that 
the results of the oral U loading test in these individuals correlated better with the results 
of genotyping than did the DPD activity in PBMCs which was used as the gold standard 
for inclusion in the present study.  
It has been reported that homozygosity for mutant DPD alleles can lead to complete DPD 
deficiency resulting in elevated concentration of endogenous pyrimidine degradation 
metabolites [22] and neurologic disorders in children. In the present study, all patients 
were heterozygous for mutant DPD alleles and were only partial DPD deficient. Catabolism 
of the pyrimidine bases thymine and U consists of three consecutive steps [13]. The high 







the enzyme responsible for pyrimdine degradation, compared with controls, could make 
identification of such patients feasible. DHU is not a metabolic end product but is further 
degraded into N-carbamyl-ß-alanine. In the present study, we found no statistical differences in 
the levels of any pyrimidine metabolites between the two study groups. Based on our results we 
see no beneficial effect of measuring these metabolites in heterozygous DPD deficient patients.
The U/DHU ratio at t = 2 hr after U ingestion appears to be an easy-to-calculate biomarker 
for predicting the U to DHU conversion rate, and can be implemented in daily practice of 
most hospitals. The HPLC equipment needed for the U and DHU assay is present in most 
hospitals laboratories or pharmacies. Based on our experience, we estimate that the cost prize 
of the oral U loading dose currently stands at around 110 Euros. Additional improvement in 
the test principle and assay could decrease this price further. A thorough cost-effectiveness 
analysis should be performed to establish total cost when this test is used in a prospective 
setting in all patients with an indication for fluoropyrimidine containing therapy. Based 
on our study results we conclude that the U/DHU ratio a t = 120 min following an oral U 
loading dose, is a suitable parameter for identifying patients at risk of developing severe 
toxicity as a result of DPD deficiency with a high sensitivity and specificity. 
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ABSTRACT
Introduction: Prospective DPYD screening reduces severe fluoropyrimidine-
induced toxicity. This study evaluated the routinely application of prospective DPYD 
screening at the Leiden University Medical Center.
Methods: Prospective DPYD screening as part of routine patient care was evaluated 
by retrospectively screening databases and patient files to determine genotype, 
treatment, dose recommendations and dose adjustments.
Results: 86.9% of all patients with a first fluoropyrimidine prescription were 
screened. 14 out of 275 patients (5.1%) carried a DPYD variant and received a 
25–50% dose reduction recommendation. None of the DPYD carriers treated with 
an initial dose reduction developed toxicities.
Conclusions: Prospective DPYD screening can be implemented successfully in a 















Fluoropyrimidines like 5-fluorouracil (5FU) and its oral pro-drug capecitabine (CAP) are 
the cornerstone anti-cancer drugs for several types of cancer such as colorectal cancer, 
head-neck cancer and breast cancer. Approximately 10–30% of the patients receiving 5FU 
or CAP experience severe (grade ≥ 3) toxicity, such as diarrhoea, mucositis and hand-foot 
syndrome [1]. 5FU is extensively metabolized (> 80%) by the liver enzyme dihydropyrimidine 
dehydrogenase (DPD). DPD is encoded by the gene DPYD for which more than 160 genetic 
variants are known, some of them being pathogenic by reducing enzyme function [2, 3]. 
There is a strong correlation between reduced DPD activity and increased risk for severe 
and potentially lethal toxicity following treatment with a normal dose of 5FU [4-7]. Toxicity 
occurred in 73% of DPYD*2A carriers, compared to 23% of wild-types [8]. Several meta-
analyses have consistently shown that DPYD*2A, c.2846A>T, DPYD*13 and c.1236C>G/
HapB3 are associated with toxicity [1, 6, 9]. Although the sensitivity of DPYD genotyping is low 
(< 14.5% for DPYD*2A and c.2846A>T combined), prospective screening for genetic variants 
in DPYD is a well-known strategy to detect patients who have reduced DPD enzyme activity 
(DPD deficient) [8, 10, 11]. Patients with no or reduced DPD enzyme activity can be treated 
more safely when applying a 25–50% dose reduction of 5FU or CAP, or using an alternative 
drug [10, 12, 13]. Recently it was shown that prospective screening for DPYD*2A followed by 
a 50% dose reduction significantly reduces the number of severe toxicities and is cost-effective 
[8]. Several pharmacogenetic guidelines are available that provide dose recommendations 
when a reduced function DPYD variant is present. The pharmacogenetic guidelines of the 
Dutch Pharmacogenetic Working Group (DPWG), recommend a 25–50% dose reduction 
of 5FU or CAP for the first treatment cycle followed by dose titration guided upon toxicity 
during subsequent cycles for patients with a variant in DPYD (DPYD*2A, DPYD*13, 
c.2846A>T or c.1236G>A). A minimum of 50% reduction or alternative therapy is advised 
for homozygous patients, depending on the variant [14]. The Clinical Pharmacogenetics 
Implementation Consortium (CPIC) [15, 16] recommends a 50% dose reduction of 5FU 
or CAP for patients with DPYD*2A, DPYD*13 and c.2846A>T and alternative therapy for 
patients who are homozygous for these variants. While these guidelines are very useful for 
dose adjustments in patients with a genetic variant, they do not advocate prospective DPYD 
testing prior to initiation of therapy. 
At Leiden University Medical Center (LUMC), a routine DPYD screening programme prior to 
prescribing 5FU or CAP was initiated in April 2013. In this retrospective study we evaluated 
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the physician’s acceptance of prospective DPYD screening for patients who were prescribed 
5FU or CAP in LUMC and the adherence of the recommended dose reduction.
METHODS 
Setting
At LUMC all patients with an indication for a fluoropyrimidine containing therapy were 
routinely screened for DPYD variants by the laboratory of the department of Clinical 
Pharmacy and Toxicology (CPT) using two independent techniques (Taqman assay and 
pyrosequencing (PSQ), described previously) [17]. Within LUMC the Electronic Medication 
Record (EMR) system EZIS (version 5.2, Chipsoft) is used, which can be consulted 
by physicians, pharmacists and nurses. DPYD genotyping results are communicated 
electronically by the responsible pharmacist into the EMR and are visible for other users 
of the EMR. 
The prospective screening programme was initiated on April 15th 2013. During a kick-off 
meeting attended by medical oncologists and fellows, the staff was informed and agreed on 
the prospective programme. New medical oncologists and fellows were informed about the 
prospective screening programme during the regular introduction programme for new staff 
members. Genotyping was performed 3 times per week (Monday, Wednesday, Friday) in 
order to minimize the lag time between sampling and test. This resulted in a turnaround time 
of 2 days, allowing rapid start of treatment if needed. Ethical approval by the Institutional 
Review Board of LUMC was not required for the current study as it evaluates standard care. 
Patient data from the EMR was handled following the Codes of Proper Use and Proper 
Conduct in the Self-Regulatory Codes of Conduct (www.federa.org).
Study endpoints
Three study endpoints were evaluated to determine the successfulness of the screening 
programme that was introduced at LUMC. We evaluated: 
1. The ‘implementation’, i.e. requests of the DPYD tests as standard care in 
daily practice;















3. The follow up of the dose recommendations by oncologists, calculated as the 
number of follow-ups of dose recommendations by prescribers, excluding 
the patients in which a follow-up was not possible (e.g. no therapy).
Study procedures
The implementation, or routinely application of the prospective (pre-treatment) DPYD 
screening in daily practice was evaluated by determining the proportion of patients who 
were screened for DPYD variants when an incident prescription for 5FU or CAP was given. 
The data was extracted from two electronic databases. The first database contains data of all 
patients who are genotyped for DPYD variants. The second database (EMR EZIS) contains 
individual patient medical records. This system is also used by oncologists to electronically 
prescribe 5FU and CAP. Prescription data prior to the start of the study was studied as 
well, to ascertain that 5FU or CAP prescription was indeed the first prescription for the 
patient. The patient identification number was used to connect data from both databases. 
Discrepancies between information in the queried databases were resolved by manually 
checking the individual electronic patient records to identify the reason of their absence 
in one of the two searches. After connecting the data from both databases, all patient data 
was anonymized. All manual changes (additional information, removal of duplicates, etc.) 
to the queries were double checked by the two first authors (CL and MS). 
To evaluate the follow up of the recommended dose reductions by the oncologists, medical 
records of patients carrying a variant in DPYD were inventoried as to determine if the 
oncologist followed the dose advice. The genotyping data of the laboratory of CPT was used 
to determine the patients carrying a DPYD variant. Prospective execution of the genotyping 
could be determined by comparing the genotyping date and start date of the therapy. Regular 
drug regimens and notations of dose reductions in the medical records were searched to 
check applied dose reductions.
After completion of the study, an explorative analysis was executed in order to describe the 
course of toxicity in relation to the provided dose recommendations. In order to perform 
this analysis, toxicity information regarding the 5FU or CAP therapy was retrieved from 
the EMR for patients with a DPYD variant. Toxicity was scored by the oncologists using the 
Common Toxicity Criteria (CTC), version 4.
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RESULTS
The implementation of the prospective screening programme for DPYD 
The prospective DPYD screening programme was implemented on April 15th 2013 (start 
date study) at LUMC. From this date until December 31st 2014 (end date study) 540 patients 
were genotyped for DPYD variants at LUMC. Initially, patients were screened only for the 
presence of the DPYD*2A variant. Later on DPYD*13, c.2846A>T and c.1236G>A were 
added to the DPYD screening. An overview is shown in Table 7.1. After removal of duplicate 
or invalid records, 529 evaluable genotyped patients remained. Of these 529 patients, 275 
patients were patients treated at the LUMC and 254 patients were treated at other hospitals, 
but genotyped as a service provided by the department of CPT of the LUMC. The dose 
reductions that were advised for each individual DPYD variant are displayed in Table 7.1.








DPYD*2A (c.1905+1G>A) 50 April 15th, 2013 529
DPYD*13 (c.1679T>G) 50 October 10th, 2013 440
c.2846A>T 50  25* October 10th, 2013 440
c.1236G>A 25 May 28th, 2014 254
Advice given by CPIC and DPWG guidelines at the time the variant was added to the routine screening.
* The dose reduction advice for c.2846A>T has been updated to 25% in February 2015.
2,498 records of 5FU or CAP prescriptions prior to December 31st 2014 were found. After 
removal of duplicates, invalid records (e.g. incomplete data) or patients not meeting eligibility 
criteria (e.g. prescription prior to April 2013), 337 patients remained who were prescribed 
5FU (16%) or CAP (84%) for the first time at LUMC within the study period. 
Genotyped patients were compared with patients who were prescribed 5FU or CAP, resulting 
in 236 matching patients. 39 patients were genotyped for DPYD, but were not prescribed 
5FU or CAP. Also, 101 patients were prescribed 5FU or CAP, but were not genotyped for 
DPYD variants (Figure 7.1). 
Two patients, who received 5FU or CAP and were genotyped, were excluded because 














the 39 patients who were genotyped without receiving 5FU or CAP therapy, 33 patients 
eventually did not start their therapy, although there was an intention to treat at the time 
of requesting the screening test. Six patients started their therapy after December 31st 2014 
and were therefore not identified by the search. Of the 101 patients with a 5FU or CAP 
prescription and no DPYD-genotyping record, the medical records were screened resulting 
in a legitimate reason not to genotype in 60 cases (Table 7.2). Legitimate reasons included; 
any notes on prior treatment with 5FU or CAP (e.g. outside LUMC) or invalid patient files 
(e.g. no medical dossier found for the oncology department). For 41 patients who had a 
Figure  7.1 Patient selection. 
Flowchart following the results from the two searches. Patients could be both genotyped and prescribed 5FU 
or CAP, or only genotyped, or only prescribed 5FU or CAP. If the intention to treat was present, patients should 
have been genotyped and these patients are ‘eligible for evaluation’.
* These two patients were excluded because their medical records revealed they had received 5FU or CAP 
prior to April 15th 2013.
** Legitimate reasons were: e.g. any notes on prior treatment with 5FU or CAP (e.g. outside LUMC) or invalid 
patient files (e.g. no medical dossier found for the oncology department).
Table  7.2 Excluded patients  
No. of patients Reason not to perform DPYD genotyping
8 5FU or CAP therapy started just prior to the start date of April 15th, 2013
30 5FU or CAP was used before April 2013 without problems and would start again after 
April 15th  
20 No medical dossier at the Medical Oncology department was found, therefore the 
patient was not treated at the LUMC
2 These dossiers were fake patients used for education purposes
Patients (n = 60) with legitimate reasons not to screen were excluded from analysis.
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prescription for newly 5FU or CAP no reason was found to neglect genotyping. After data 
cleaning, 314 patients with a newly 5FU or CAP prescription remained in the dataset and 
273 of these patients were genotyped as depicted in Figure 7.1. The clinical acceptance of 
the prospective DPYD screening programme is displayed as percentage per month in Figure 
7.2. The average clinical acceptance was 86.9%.
The clinical acceptance of the prospective DPYD screening programme is displayed as 
percentage per month in Figure 7.2. The average clinical acceptance was 86.9%.
Proportion of test results with a dose recommendation 
During the study period 275 patients were screened for DPYD variants. Of these 275 
patients, 14 patients (5.1%) were found to carry one or more variants. Shown in Table 7.3 
are the variants that were screened for, and of each variant the frequency in comparison to 
the literature.
Table  7.3 DPYD variants
DPYD variant # # of tested patients % LUMC % literature
DPYD*2A / c.1905+1G>A 6 275 2.2 ~1.0–1.8 [10, 18]
DPYD*13 / c.1679T>G 0 214 0 ~0.1 [12]
c.2846A>T 1 214 0.5 ~1.0–1.4 [10, 12]
c.1236G>A 8 109 7.3 ~2.6–4.9 [10, 19]
TOTAL 15 (n = 14) 275 5.1 4.7-8.2
DPYD variants found in LUMC patients and these numbers compared to frequencies in the literature.
For eight patients with a c.1236G>A variant a dose reduction of 25% was recommended. Five 
patients with a DPYD*2A variant received a recommendation to reduce the dose by 50%. 
One patient carried both DPYD*2A and c.2846A>T (Table 7.4, patient 9). For this patient 
no dose reduction was recommended. Instead it was advised to determine the DPD enzyme 
activity in PBMCs as applied Taqman and PSQ assays were not able to identify if the found 
mutations were in cis or trans configuration. Turnaround time of the DPD enzyme activity 
test is approximately 1–2 weeks, which could not be awaited for. The treating physician 
decided to treat this patient with a 50% dose reduction, taking into account the results of 
the genotyping and the fact that this patient had tolerated 5FU-containing regimens before. 
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Fluoropyrimidine therapy was stopped in this patient after the first cycle due to toxicity 
(≤ grade 3).
The follow up of the dose recommendations by oncologists
Dose reduction was advised after the first administration of 5FU or CAP (post-dose) for 
2 patients. The medical record of the first patient showed that the initial screening result 
became available after the start of therapy. Dose adjustments could not be applied, toxicity 
occurred and the advised dose reduction was applied in the second cycle (Table 7.4, patient 
12). The other patient was screened after start of therapy, but stopped therapy completely 
due to toxicity, thus applying a dose reduction was not applicable. For this patient the reason 
not to screen prospectively was absent in the medical record (Table 7.4, patient 2). 
For eleven patients a dose reduction was recommended prior to the start of therapy 
(prospective). This resulted in an initial dose reduction in 8 out of 11 patients. For one patient 
the recommend dose reduction was not applied and full dose was given (Table 7.4, patient 
13). In two patients the recommended dose reduction could not be applied since they did 
not start therapy. One patient did not start therapy due to renal failure and the presence of 
a DPYD variant (Table 7.4, patient 14), and one patient refused to start therapy (Table 7.4, 
patient 5). Also one patient was genotyped prospectively, but received a recommendation 
for phenotyping due to compound heterozygosity (Table 7.4, patient 9). This patient started 
treatment with a 50% reduced dose at the oncologists discretion. An overview of the above 
mentioned data is displayed in Table 7.4. The adherence to the dose recommendations 
(pre- and post-dose) is 90% (9 out of 10).
Analysis of results on clinical outcomes 
The explorative analysis showed that the prospective dose recommendations given, resulted 
in initial dose reductions in eight patients. None of these eight patients developed severe 
toxicity (grade ≥ 3) during the first cycle. After the first or second cycle it was possible to 
increase the dosages, guided by toxicity. Dosages were increased in four patients (from 50% 
up to 60, 80 and 100%, and from 75% to 100%, respectively, all receiving CAP). However, 
this led to the development of severe toxicity in two DPYD*2A carrying patients (80% CAP 
led to diarrhoea grade 3 followed by 31 days of hospitalisation and 100% CAP led to hand-














In one patient with a DPYD*2A variant who received CAP in combination with radiotherapy, 
the dose recommendation was not followed by the physician and this patient experienced 
diarrhoea (grade 4), enteritis and leukopenia, for which hospitalisation of 18 days was 
required and CAP therapy was permanently terminated (Table 7.4, patient 13).
DISCUSSION
In this study, the successfulness of routine application of a prospective DPYD screening 
programme followed by pharmacogenetically guided dose recommendations was studied. 
The percentage of patients in which screening was performed was relatively high: 86.9% of 
all eligible (newly prescribed 5FU or CAP) patients. In the study period, 13.1% of the patients 
were not screened prior to receiving 5FU or CAP therapy, which on average comes down to 
one patient per month. Follow-up of dose recommendations given by the pharmacist were 
applied in all cases except one, resulting in a high acceptance.
Our study has several limitations. Due to the retrospective design of our study, available 
data may not always have been fully complete. For example for some patients, it was not 
possible to retrieve why DPYD screening was not requested or whether a patient actually 
started fluoropyrimidine therapy. In addition, the study was performed with data obtained 
in a real world clinical setting instead of a regulated and controlled case report form. We 
had to manually check patient files to obtain specific information and not all physicians 
may have systematically annotated CTC grading continuously to describe toxicity. Due 
to the low number of DPYD variant carriers our study was not powered to formally test 
the effect of DPYD screening on fluoropyrimidine-induced toxicity and only explorative 
analyses could be performed.  
In this study we determined the level of routine application of DPYD screening in daily 
practice, which increased at the end of the study period to 90–100%. This might indicate 
that prescribers were undergoing a learning or acceptance curve following the initial start, 
and were getting used to apply DPYD genotyping increasingly in their daily routine.
We believe patients do not need to be genotyped if previous 5FU or CAP usage without 
toxicity is known or if patients were genotyped (DPYD) or phenotyped (DPD) previously. 
However, within the 41 (13.1%) remaining patients legitimate reasons can still exist (e.g. 
well-tolerated treatment before 2013 with 5FU or CAP), but might not have been filed in 
the medical record. Therefore we can conclude the 90–100% (≤ 1 patient not tested per 
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month) rate was an effective prospective DPYD screening implementation. Disputable is, 
if this clinical acceptance can become 100% continuously. In order to support the clinical 
implementation, the use of a clinical decision support (CDS) system might be suitable. In 
LUMC a CDS entitled adverse drug event alerting system (ADEAS) is used in daily practice 
in the hospital pharmacy of LUMC [20]. This system is used by hospital pharmacists to 
systematically select patients at risk of possible adverse drug events. It retrieves data from 
several information systems, and uses clinical rules to select the patient at risk of adverse 
drug events. 
As mentioned before, sensitivity of genotyping is relatively low (< 14.5% for DPYD*2A 
and c.2846A>T combined) [11]. Even if all patients with a DPYD variant are identified and 
treated with an appropriately reduced dose, not all fluoropyrimidine-related toxicity can be 
prevented. Adding a DPD phenotyping test may increase sensitivity, but is expensive and 
logistically challenging to implement in clinical practice [13]. SNPs located in other genes 
than DPYD (e.g. TYMS) have been associated with fluoropyrimidine-induced toxicity with 
conflicting results. However, testing for these SNPs holds the potential to increase sensitivity 
[21]. Even though DPYD screening cannot prevent all fluoropyrimidine-related toxicity, we 
feel that the available evidence strongly supports implementation in clinical practice and 
can prevent fluoropyrimidine-induced deaths [8, 11, 22]. 
The presence of one of the four DPYD variants that were pre-emptively tested resulted in 
a recommendation to the oncologist to reduce the initial dose of 5FU or CAP by 25–50% 
depending on the identified variant. In February 2015 the recommended dose reduction 
for c.2846A>T was changed from 50% to 25%, following the updated guidelines of the 
DPWG [23, 24]. 
One patient (Table 7.4, patient 13) received full CAP dose, since the treating oncologist argued 
that she was afraid of under dosing the patient as the dosage of CAP in chemoradiation 
schemes is already lower compared to other treatments and there is less opportunity to 
increase the dose in subsequent treatment cycles. The patient developed severe toxicity 
illustrating that the recommended dose reductions should also be applied to lower CAP 
doses used in chemoradiation, despite lack of published data about CAP toxicity during 
chemoradiation therapy.
In conclusion, this study for the first time shows that systematic prospective DPYD screening 














dose reduction for patients with a DPYD variant resulted in absence of toxicity. However, 
a more active follow-up of adherence to provided dose recommendations might improve 
patient safety even further. 
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Introduction 
Since its approval in the 1960s, the fluoropyrimidine 5 fluorouracil (5-FU) has been 
extensively used, either as single agent or in combination with other drugs or radiotherapy 
in the treatment of many types of cancer such as breast, anal, vulvar, head and neck, and 
gastrointestinal cancer. In the last decades, 5-FU is increasingly used in an oral formulation, 
as the pro-drug capecitabine. The use of fluoropyrimidines often results, like other cytotoxic 
chemotherapeutic drugs, in undesired toxicity. The incorporation of the 5-FU metabolite 
fluorouridine triphosphate (FUTP) into RNA and inhibition of thymidylate synthase 
by FdUMP, underlying the antineoplastic effect in tumour cells, also interfere with the 
metabolism of normal, rapidly proliferating cells like the gastrointestinal mucosa, bone 
marrow, hair follicles and nail beds leading to leukopenia, alopecia, mucositis and stomatitis 
[1]. The first sign of 5-FU systemic toxicity is often stomatitis, varying from mild erythema 
to haemorrhagic ulceration of the oral cavity. Frequently, stomatitis is accompanied by 
diarrhoea. The effect of 5-FU on the brain stem can cause nausea and vomiting during 
administration and its effect on the skin can cause hyperpigmentation and hand-foot 
syndrome or when used in combination with radiotherapy skin inflammation and ulceration. 
Besides these expected therapy related toxic effects, in a small proportion of fluoropyrimidine 
treated patients, extreme toxicity is observed. It has become clear that a large part of this 
severe toxicity is caused due to a partial or complete dihydropyrimidine dehydrogenase 
(DPD) deficiency and hence, a strongly reduced capacity to degrade 5-FU into metabolites 
[2-6]. DPD deficiency, however, can not explain the toxicity in all patients. There may be 
several reasons for this. Fluoropyrimidines are often used in combination treatments with 
other cytotoxic drugs or radiotherapy, and a contributory effect of non-fluoropyrimidines 
in the toxicity observed. Alternatively, polymorphisms involving genes other than DPYD 
(gene encoding for DPD) that play a role in fluoropyrimidine metabolism may cause non-
DPD related toxicity. For example variants in the TYMS gene will lead to reduction of the 
enzyme thymidylate synthase. In breast cancer patients homozygous for the TYMS 3RG 
allele, have a significantly higher incidence of toxicity and a lower response was observed 
when compared to heterozygous patients, and patients in which the TYMS 3RG allele was 
not present [7]. In addition, the presence of the TYMS 2R/2R variant was also associated 
with higher toxicity [8]. Variants in the dihydropyrimidinase coding gene, DPYS, were 
likely to cause structural destabilization and protein misfolding [9] and patients with a 




















[10]. For the β-ureidopropionase enzyme which catalyzes the last step in the 5-FU and 
uracil-degradation pathway, it is suggested that variants of the UPB1 gene coding for 
β-ureidopropionase are likely to be associated with increased toxicity although the role of 
these variants are less significant than alterations in DPYD [11-13].
Besides its role in 5-FU pharmacokinetics and toxicity, the level of DPD present in tumour 
cells is likely to be correlated to 5-FU resistance and treatment response. Indeed, prospective 
studies in colorectal cancer patients showed that overexpression of thymidylate synthase 
and DPD in certain types of tumours may explain the resistance to 5-FU therapy [14-16]. 
A similar correlation was found for bladder cancer [17], and for lung cancer where a high 
DPD expression in NSCLC tumour cells is correlated with EGFR mutations [18].
The examples given in the previous paragraphs show that the individual’s genotype greatly 
influences the behaviour of a drug. Pharmacogenetics, the heritability of drug response, 
may help to explain some of the variability in drug response between individuals [19]. 
However, besides the variation in drug response caused by the genotype of an individual, 
non-genetic factors such as age, organ function, food, smoking status, concomitant therapy, 
drug interactions and nature of the disease may also influence the drug’s effect in an 
individual [20]. 
DPD is encoded by the gene DPYD for which 567 coding genetic variants are currently known 
[21], some of them being pathogenic since they reduce enzyme function or stability [22, 
23]. We hypothesized that variability in DPD activity and its effect on DPD related toxicity 
could be best examined by a phenotyping approach, since current DPYD genetic testing 
only explains part of the fluoropyrimidine-related toxicity. Tests based on phenotyping 
approaches are already known and used in pharmacokinetics research, such as probes for 
phase I and phase II metabolic enzymes and drug transporters [24]. In this thesis, uracil 
being used as an oral loading dose is studied as a probe for DPD deficiency in cancer patients 
treated with fluoropyrimidines and our aim was to develop a test procedure that is suitable 
to be incorporated broadly into daily practice in hospital care.
Status of DPD testing
Several tests have been developed aiming to predict or explain DPD related fluoropyrimidine 
toxicity [25] (Chapter 2). These tests include both genotyping and phenotyping-based assays. 
To date, in daily practice, DPD testing is often used as counselling for family members of 
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DPD deficient subjects or in a retrospective setting to provide an explanation for severe 
fluoropyrimidine related toxicity. In our view this is not useful, as the toxicity then already 
has taken place and the aim is to avoid toxicity. The prospective screening of DPD deficiency 
is only used sparsely internationally, but was recently successfully implemented in a number 
of hospitals in the Netherlands (Chapter 7). The severity of DPD related toxicity is illustrated 
by prolonged hospitalization and by its rare, but potential lethal outcome [26, 27]. This 
observation raises the question why prospective DPD testing is not yet adopted as standard 
care in the field of oncology.
The successfulness of a diagnostic test or screening method
There are numerous guidelines and criteria for appraising diagnostic test studies and diseases 
[28-30]. It is interesting to investigate to what extent these criteria for diagnostic tests are met 
for routinely DPD screening in patients with an indication for fluoropyrimidine containing 
therapy. One of the criteria for a diagnostic test state that there should be a suitable test or 
examination to detect DPD related toxicity. The term suitable can be interpreted in multiple 
ways, and makes it unclear to what extent a test has to be validated or studied to be considered 
as suitable. In recent history, there are several well examples of diagnostic tests in the field 
of oncology that have been accepted by oncologists and were implemented broadly within a 
short period. Interestingly, for these tests, no prospective clinical trial was performed. This 
is illustrated by the discovery of Kirsten rat sarcoma viral oncogene (KRAS) mutations and 
its role in the treatment of colorectal cancer with cetuximab and panitumumab. It was first 
discovered that cetuximab had little or no effect in colorectal tumours harbouring KRAS 
mutation [31, 32]. Patient selection by analysis of KRAS mutations has been a fundamental 
event to increase efficiency and reduce cost after multiple retrospective studies all showed the 
same results [33]. Recently this was extended to RAS wild type tumours. Apparently a strong 
biological rationale and effect (shown by multiple retrospective studies all showing the same 
direction of effect) doesn’t need a prospective randomised study to change clinical practice.
It is remarkable that KRAS testing was successfully implemented while DPD testing is still 
under discussion. With KRAS testing, there is a very clear correlation between the test result 
and the treatment outcome. This is not fully the case with prospective DPD testing. It is 
obvious that DPD testing can prevent 5-FU related toxicity, however, not all 5-FU toxicity 
can be explained by reduced DPD activity. This is illustrated by the fact that approximately 




















activity and [34, 35] and it is thus important to realize that prospective testing for DPD 
deficiency will not exclude all 5-FU related toxicity. 
An important criterion for a diagnostic test is that the cost of case-finding (including 
diagnosis and treatment of patients diagnosed) should be economically balanced in 
relation to possible expenditure on medical care as a whole. Prospective screening for 
DPD deficiency can reduce treatment costs by preventing toxicity initiated by low DPD 
activity. Severe Common Toxicity Criteria (CTC) grade III or IV toxicity might lead to 
hospitalization of patients for several days at high care units or even death (grade V). 
Ideally to be cost effective, the costs of prospective testing must be in favour to the costs of 
treatment of toxicity due to DPD deficiency. The prevalence of partial DPD deficiency in 
Caucasian population is approximately at least 3% [36-38]. As a result, many patients with 
an indication for fluoropyrimidine-containing therapy need to be screened prospectively 
in order to diagnose the minority with DPD deficiency. Nevertheless, it was described that 
the average total treatment cost per patient was lower with a prospective DPD screening 
strategy compared to nonscreening [39]. 
Importantly, the test result of a diagnostic test should lead to an actionable, clinical 
recommendation, or in the case of DPD deficiency, to a fluoropyrimidine dose adjustment 
or advice for alternative therapy. The test result of DPD deficiency measured in PBMCs can 
present as a complete or partial malfunction of the enzyme and there is a linear correlation 
between DPD activity and 5-FU clearance [40]. For the genotyping approach in which DPYD 
variants are determined, there are clear dosing advices that are related to the presence of 
DPYD variants, though there is data available that the toxicity risk of certain DPYD variants 
is also influenced by factors such as gender, mode of administration and co-treatment 
with folinic acid [41]. Chapter 7 shows, that it is possible to implement prospective DPYD 
screening effectively in a hospital setting, with the result that 90–100% of all patients with 
an indication for a fluoropyrimidine containing therapy are being screened.
Evaluation of the oral uracil loading dose
Uracil is not registered for human use, but the quality of commercially available uracil is 
very high without impurities as is described in Chapter 3 and can be used safely in patients. 
The safety of oral uracil is further demonstrated by the fact that there were no side effects 
of any form observed in all subjects following the administration of the uracil loading dose. 
Uracil in plasma can be determined by High Pressure Liquid Chromatography (HPLC) of 
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with HPLC-mass spectrometry. This equipment is present in clinical or pharmaceutical 
laboratories in hospitals. The uracil dose that was used in this thesis is 500 mg/m2. There is 
a disadvantage of a uracil dose that is based on the body surface area (BSA) of patients since 
this requires individual doses of uracil have to be on stock or prepared by the pharmacy. 
In Chapter 4 and 5 an intensive blood-sampling scheme was used in order to establish 
comprehensive plasma-concentration curves of uracil following oral intake. Because a full 
sampling scheme and the associated test length of 4 hours can be considered as patient 
unfriendly, it was replaced by a limited sampling schedule in which blood is taken after 
60 and 120 minutes following uracil ingestion. Is this feasible in daily clinical practice 
and patient-friendly enough? There are other diagnostic tests based on the same blood 
sampling principle that are accepted and implemented broadly, and used successfully. As an 
example, the oral glucose tolerance test is used to diagnose diabetes and gestational diabetes 
mellitus defined as glucose intolerance identified during pregnancy [42, 43]. Diabetes may 
be diagnosed based on HbA1C criteria or plasma glucose criteria, either the fasting plasma 
glucose or the 2-hour plasma glucose value after a 75-g oral glucose tolerance test. The use 
of this glucose test shows that it is indeed possible that the oral uracil loading in its present 
form is suitable to be incorporated into daily practice in hospitals. 
Patient selection and uracil pharmacokinetics
In this thesis, uracil was orally administrated to healthy volunteers and cancer patients with, 
and without DPD deficiency. All study subjects who were tested, were Caucasian which is 
interesting, since differences are reported in DPD activity among different populations. The 
prevalence of DPD deficiency is 3–5% in a European/Caucasian population, but is estimated 
at approximately 8% for the African-American population [37, 44]. This difference in 
prevalence will not influence the test result of the oral uracil loading dose. Genetic variations 
in DPYD might be unique depending on race and were investigated for different ethnical 
groups in which several DPYD variants showed different distributions [45-48]. In addition, 
differences in pyrimidine catabolism have been reported between men and women. In 
general women suffer more from side effects during fluoropyrimidine-containing therapy 
[49-52]. A possible explanation may be the lower clearance of 5-FU in women compared to 
men [53]. Moreover, differences have been observed in endogenous uracil and dihydrouracil 
levels between men and women, but the mean uracil/dihydrouracil ratio was comparable 
[54]. For the oral uracil loading dose, it was not investigated if uracil pharmacokinetics and 




















In Chapter 5 we showed that the presence of metastatic disease in colorectal cancer patients 
has no effect on uracil pharmacokinetics. This is in line with the observation that extensive 
hepatic replacement due to liver metastases had no effect on 5-FU pharmacokinetics 
indicating that the amount of DPD is probably not influenced by moderate reduction in 
liver function [55]. The gastrointestinal absorption of uracil is a pharmacokinetic first order 
process and the elimination follows a saturable Michaelis-Menten kinetics [56]. Of note, all 
patients that were included in the studies described in this thesis had an intact gastrointestinal 
(GI) tract. Surgical alteration of the structure of the GI tract such as gastric or bowel resection, 
may alter its function which can have impact on drug absorption [57]. For this reason, the 
oral uracil loading dose is not suitable for patients with such GI alterations and alternative 
testing has to be performed.
In this thesis, the oral uracil loading dose was not used in a prospective setting. All patients 
already received one or multiple dose of 5-FU or capecitabine before they received the 
oral uracil test dose. They were included based on the DPD activity that was assessed by 
measuring the DPD activity in peripheral blood mononuclear cells (PBMCs) [58] and in 
Chapter 6 severe toxicity occurred before DPD activity was measured. Despite the fact the 
uracil loading was not investigated in a true prospective setting, the test was applied to a 
variable group of patients with and without toxicity, variable DPD activity and with and 
without metastatic disease.
Future perspectives
The results in this thesis indicate that the oral uracil loading dose is suitable as a phenotyping 
probe for DPD deficiency and can be incorporated into daily practice in hospital care. As 
mentioned before the equipment for analysing the plasma samples is already present in 
most hospitals, so that the turnaround-time of the test can be short with 1 or 2 days. The 
local pharmacy can order or prepare the uracil that is needed for the test as long as there is 
no commercially uracil solution available. Most hospitals in the Netherlands have special 
wards that are used for short stay of patients or the clinical laboratories can handle the 
patient logistic that is needed to perform the test. 
Nevertheless, the test still might be optimised to simplify the test procedure in order to 
further increase acceptance and applicability. Since the uracil/dihydrouracil ratio after uracil 
ingestion is determined by DPD enzyme activity and not so much by the dose administered, 
a fixed dose uracil will not influence the test result and is for practical reasons preferred 
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over the BSA determined dose of a subject that was used in this thesis. Subsequently, a 
dried blood spot sampling might be candidate to replace the venous sampling method that 
is currently used. 
Pharmacokinetics can be used as a tool to optimise 5-FU therapy. With PK guided 5-FU 
dosing, the start dose of 5-FU is based on BSA and titrated during following administration 
based on 5-FU plasma concentration and AUC [59, 60]. Besides its role in diagnosing DPD 
deficiency, the oral uracil loading dose might be useful to establish a more specific 5-FU 
starting dose when therapy is started close to the desired plasma level and Area Under the 
Curve if a clear relation exists between uracil and 5-FU PK. 
Although not studied in this thesis, it may be interesting to investigate if the oral uracil loading 
dose can play a role in individual pharmacokinetically (PK) guided 5-FU dosing. This 5-FU 
dosing approach leads to higher efficacy and tolerability compared to 5-FU dosing based on 
BSA. It has already been suggested that the use of 5-FU Michaelis-Menten pharmacokinetic 
models might be suitable to predict a-priori 5-FU plasma concentrations [61]. 
The genotyping strategy that was evaluated in Chapter 7 can be further improved. There 
are more DPYD variants than the four tested that alter DPD enzyme activity, and novel 
variants are still discovered. The presence of one of these non-tested variants potentially 
will lead to a false negative test result with the risk to develop toxicity. Since the costs for 
genotyping continues to decrease [62, 63], the number of DPYD variants tested could be 
expanded to improve sensitivity. The variants that are tested in the current test strategies are 
mostly coding variants, but there have been pathogenic variants described in the noncoding 
DPYD gene regions that are not routinely tested [64]. This can be resolved by sequencing 
the entire DPYD gene, but although more informative, this is far more expensive than the 
strategy that was used in Chapter 7.
This thesis does not answer the question which DPD test strategy is the most efficient one 
to prevent and predict DPD related toxicity. This requires the multiple test strategies being 
compared to each other in a prospective, head to head study in which the outcome should 
be the prevention of fluoropyrimidine related toxicity. At this moment a large prospective, 
multicentre study is performed in which different strategies to prevent DPD related toxicity 
are evaluated (EudraCT registration number: 2014-005064-15).
Despite the fact that the cost effectiveness of DPD screening should be investigated more 




















DPD testing, irrespective of what specific test is used, should be standard care and 
incorporated in oncology guidelines. We advocate that all patients who are first time treated 
with a fluoropyrimidine containing therapy should be screened for DPD deficiency.
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Summary / SamenvattingChapter 9
9.1  SUMMARY
Fluoropyrimidines have been used in the treatment of different types of cancer for 
many decades. The most common fluoropyrimidine is 5-flourouracil (5-FU), which is 
administered intravenously as a bolus or as prolonged infusion. 5-FU itself is not available 
in an oral presentation form. It is, however, converted by thymidine phoshorylase in the 
metabolic pathway of the oral 5-FU prodrug capecitabine. Many tissues throughout the 
body express thymidine phosphorylase. Some human carcinomas express this enzyme in 
higher concentrations than surrounding normal tissues. Dihydropyrimidine Dehydrogenase 
(DPD) is involved in the degradation of endogenous pyrimidine bases uracil and thymine, 
but also in the degradation of 5-FU. More than 80% of the amount of 5-FU administered 
is catabolized primarily in the liver where DPD is abundantly expressed. DPD is encoded 
by the DPYD gene for which 567 coding variants are known to date, some of them being 
pathogenic by reducing enzyme capacity. Interindividual variability in the activity of DPD 
influences 5-FU pharmacokinetics and a reduced DPD activity can lead to severe toxicity 
and even death following administration of 5-FU or capecitabine. Knowledge regarding the 
clinical impact of reduced DPD activity on the pharmacokinetics and pharmacodynamics of 
fluoropyrimidines may be useful to dose-individualized therapy of 5-FU and capecitabine. 
In this thesis, an in depth overview is provided of methods and their potential to optimize 
fluoropyrimidine dosing based on individual DPD enzyme activity. Furthermore an oral uracil 
loading dose as probe for DPD deficiency in cancer patients treated with fluoropyrimdines 
for this purpose is studied. 
In Chapter 2 an overview of the literature is presented on predictive tests that have been 
described until 2016 for screening for dihydropyrimidine dehydrogenase deficiency. Tests 
based on assessing DPD enzyme activity, genetic variants in DPYD and mRNA variants 
have been studied for screening for DPD deficiency, but only few are sparsely implemented 
into clinical practice in a prospective setting, or are only used in a retrospective setting. A 
problem with many tests is that they require expensive equipment that is not available in 
every hospital or that analytical procedures are laborious, and for that reason not applicable 
to screen large numbers of patients. Beside these practical drawbacks, there is a no consensus 
about the definition of DPD deficiency and definition of selectivity and specificity of the 
tests. If determined, they are not related to the same endpoint, which makes it even harder 
to compare the efficacy of the various tests. Future studies should focus more on cost-














is most suitable to predict patients at risk of developing severe fluoropyrimidine related 
toxicity caused by DPD deficiency. 
Like 5-FU, uracil is metabolised by DPD. The measurement of plasma uracil levels following 
administration of an oral uracil loading might be indicative for the DPD activity of an 
individual patient and might thus be able to prevent severe fluoropyrimidine related toxicity. 
In Chapter 3 the Investigational Medicinal Product Dossier (IMPD) for uracil is presented. 
The IMPD is the basis for approval of clinical trials by the competent authorities in the EU. 
It was used for the medical ethical approval of the studies that were performed with uracil 
powder since uracil is not registered for human use. All paragraphs of the IMPD were 
written for uracil and all tests considering impurities, assays and quality were performed 
by an analytical monograph with the use of liquid chromatography with UV photo diode 
array detection. Acceptance criteria were derived from the European Pharmacopeia General 
Monograph. The manufacturing of the uracil study medication was performed under Good 
Manufacturing Practice and Good Clinical Practice conditions. 
The pharmacokinetics of uracil should only depend on DPD activity and should not be 
influenced by disease status or differ between healthy volunteers and cancer patients. In order 
to exclude this last aspect, in Chapter 4 the results of a pharmacokinetic study are described 
that investigates the differences in uracil pharmacokinetics in healthy volunteers and DPD 
deficient patients following administration of an oral uracil loading dose in two doses. 
The use of higher uracil doses is expected to result in a more adequate discrimination 
between normal and deficient individuals due to a prolonged DPD enzyme saturation in 
DPD-deficient subjects compared with lower doses of uracil. Secondary objective of the 
study performed in Chapter 4 was to investigate linearity of uracil pharmacokinetics at 
increased uracil dose and the intra- and interday variation in uracil pharmacokinetics. The 
conclusion of this study was that uracil administration at a single dose of 500 mg/m2 Body 
Surface Area (BSA) leads to significant and reproducible differences in pharmacokinetics of 
uracil and dihydrouracil between volunteers with a normal DPD activity and DPD-deficient 
patients. Uracil doses above 500 mg/m2 have no higher discriminating potential to distinguish 
between subjects with and without DPD deficiency. Uracil dose elevation will only result 
in a shift to the right of the uracil and dihydrouracil concentration curve and unnecessary 
longer exposition to high uracil levels. 
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Uracil metabolism by DPD takes mainly place in the liver. Hence, the presence of liver 
metastasis might influence uracil pharmacokinetics following administration of oral uracil. In 
Chapter 5 the uracil dose of 500 mg/m2 BSA was further studied and compared in adjuvantly 
treated colon cancer patients, and colorectal (CRC) patients with metastatic disease. The 
results of this study showed that in patients with a normal DPD activity, with the exception 
of C
max
, there is no difference in uracil pharmacokinetics in patients with metastatic CRC 
compared to colon cancer patients that are treated adjuvantly. 
The pharmacokinetic profile of uracil in the former two studies were established with the 
use of an intensive blood sampling scheme that is not ideal for use in a clinical setting. 
Therefore in Chapter 6 the oral uracil loading dose was further evaluated (i) to develop a 
limited sampling strategy, (ii) to detect decreased uracil elimination in patients with a DPD 
deficiency and (iii) to perform a more in-depth quantitative compartmental pharmacokinetic 
analysis of uracil plasma concentrations. In this study, several pharmacokinetic parameters 
were determined and compared to each other, leading to the conclusion that the uracil/
dihydrouracil ratio at t = 120 min following the oral uracil loading dose is the most suitable 
parameter for identifying patients at risk of developing severe DPD related toxicity with a 
high sensitivity and specificity. 
The Investigator Brochure of capecitabine states that its use is contraindicated in patients with 
a known DPD deficiency, that is defined as rare, unexpected and severe toxicity. For 5-FU, 
the investigator brochure indicates that when applicable, DPD enzyme activity should be 
measured prior 5-FU treatment. Until now, prospective DPD screening is not yet considered 
standard care in oncology practice and are not advocated in ESMO or Dutch guidelines. 
This may be a result of the fact that there is no consensus internationally about the optimal 
strategy to identify patient at risk of developing DPD based toxicity. Despite this, there 
are however well organised initiatives involving a prospective DPD test setting. Chapter 7 
describes a study that evaluates a routine DPYD screening programme in a Dutch academic 
center prior to prescription of 5-FU or capecitabine. In this study, the physician’s acceptance 
of prospective DPYD screening for patients who were prescribed 5-FU or capecitabine and 
the adherence of the recommended dose reduction were evaluated. The number of patients 
in which screening was performed was relatively high with 86.9% of all eligible patients and 
follow-up of dose recommendations given by the pharmacist was possible in most cases. 
This study showed that implementation of prospective DPYD screening is feasible and can 














In Chapter 8 the results of the studies performed in this thesis are discussed in a broader 
setting and future perspectives are mentioned regarding improving the oral uracil loading 
dose and prospective DPD screening in general. Despite further improvements of the test 
procedure, the oral uracil loading dose in its present form has potential as a phenotyping 
probe for DPD deficiency in a prospective setting.
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9.2  SAMENVATTING
Fluoropyrimdines worden al decennia lang gebruikt ter behandeling van verschillende 
soorten kanker. De meest bekende fluoropyrimdine is 5-fluorouracil (5-FU) dat intraveneus 
als bolus of langlopend infuus kan worden toegediend. 5-FU als stof zelf is niet beschikbaar 
in een orale toedieningsvorm, maar wordt gevormd door thymidine fosforylase uit de 
metabolieten van de orale 5-FU prodrug capecitabine. Veel weefselstructuren in het lichaam 
bevatten thymidine fosforylase. Sommige humane carcinomen bevatten dit enzym echter 
in hogere concentratie dan omliggend weefsel. Dihydropyrimidine dehydrogenase (DPD) 
is betrokken bij de afbraak van de endogene pyrimidine basen uracil en thymine, maar ook 
bij de afbraak van fluoropyrimidines. Meer dan 80% van de hoeveelheid 5-FU toegediend, 
wordt voornamelijk afgebroken in de lever waar DPD voornamelijk aanwezig is. DPD wordt 
gevormd uit het DPYD gen waarvoor op dit moment 567 coderende varianten beschreven 
zijn en waarvan sommige pathogeen zijn doordat ze de enzymactiviteit verminderen.
Interindividuele variatie in DPD-activiteit beïnvloedt 5-FU farmacokinetiek en verminderde 
DPD-activiteit kan leiden tot ernstige toxiciteit en zelfs overlijden ten gevolge van 5-FU of 
capecitabinegebruik. Kennis over de klinische gevolgen van verminderde DPD-activiteit en 
de farmacodynamiek van fluoropyrimidinen kan behulpzaam zijn bij individueel doseren van 
5-FU en capecitabine. In dit proefschrift wordt een dieper overzicht gegeven van methoden 
en het potentieel daarvan om het doseren van fluoropyrimidinen te optimaliseren op basis 
van de individuele DPD enzymactiviteit. Aanvullend wordt een orale uracil belastingtest 
bestudeerd die geschikt zou kunnen zijn om DPD-deficiëntie op te sporen in kankerpatiënten 
die behandeld worden met fluoropyrimidinen.
In hoofdstuk 2 wordt een overzicht gegeven van beschikbare literatuur over voorspellende 
testen voor DPD-deficiëntie die beschreven zijn tot 2016. Er zijn testen bestudeerd die 
gebaseerd zijn op het schatten van de enzymactiviteit en genetische variaties in DPYD en 
mRNA, maar er zijn maar enkele testen spaarzaam geïmplementeerd in de kliniek in een 
prospectieve setting. Een probleem met veel testen is dat deze dure apparatuur vereisen die 
niet in elk ziekenhuis beschikbaar is, of dat de testmethode zeer bewerkelijk is en om die 
reden niet geschikt om grote aantallen patiënten te testen. Naast deze praktische nadelen is er 
ook geen consensus over de definitie van DPD-deficiëntie en zijn selectiviteit en specificiteit, 
indien bepaald, niet gecorreleerd aan dezelfde eindpunten waardoor het lastig is om testen 
qua effectiviteit onderling te vergelijken. Toekomstig onderzoek zou zich meer moeten 














meest geschikt is om te voorspellen welke patiënten het risico lopen om fluoropyrimidine-
gerelateerde toxiciteit te ontwikkelen veroorzaakt door DPD-deficiëntie.
Uracil wordt net als 5-FU gemetaboliseerd door DPD. Het meten van uracil plasmaspiegels 
na toediening kan indicatief zijn voor de DPD-activiteit in een individuele patiënt en kan 
ernstige fluoropyrimidine-gerelateerde toxiciteit voorkomen. In hoofdstuk 3 wordt het 
Investigational Medicinal Product dossier (IMPD) gepresenteerd dat de basis is voor het 
goedkeuren van klinisch onderzoek door bevoegde instanties in de Europese Unie. Het 
IMPD is gebruikt voor de medisch-ethische toetsing van de studies die met uracilpoeder 
zijn uitgevoerd, aangezien uracil niet geregistreerd is voor humaan gebruik. Alle paragrafen 
van het IMPD zijn toegespitst op uracil en alle testen met betrekking op onzuiverheden, 
gehalte-analyses en kwaliteit zijn uitgevoerd aan de hand van een analytische monografie 
met behulp van vloeistofchromatografie in combinatie met UV-foto diode array detectie. 
Acceptatiecriteria zijn afgeleid van de Europese farmacopee General Monograph. Het 
bereiden van de uracil studiemedicatie werd uitgevoerd onder Goede Manier van Produceren 
(GMP) en Good Clinical Practice (GCP) omstandigheden.
De farmacokinetiek van uracil zou alleen af moeten hangen van DPD-activiteit en 
niet worden beïnvloed door ziektebeeld of verschillen tussen gezonde vrijwilligers en 
patiënten. Om dit laatste uit te sluiten zijn in hoofdstuk 4 de resultaten beschreven van 
een farmacokinetische studie waarin het verschil in uracil farmacokinetiek tussen gezonde 
vrijwilligers en DPD-deficiënte patiënten is onderzocht na toediening van een orale uracil 
belastingtest in twee doseringen. 
De verwachting was dat het gebruik van een hogere dosis uracil tot een duidelijker 
onderscheid leidt tussen normale en deficiënte individuen als gevolg van verlengde DPD 
enzymverzadiging in DPD-deficiënte personen ten opzichte van de lagere uracildosis. Het 
tweede doel van de studie die in hoofdstuk 4 is uitgevoerd was het onderzoeken van de 
lineariteit van uracil farmacokinetiek bij een verhoogde dosering uracil en de intra- en 
interdagvariatie van uracil farmacokinetiek. 
De conclusie van deze studie is dat uraciltoediening op basis van een dosering van 500 
mg/m2 lichaamsoppervlak leidt tot significante en reproduceerbare verschillen in uracil 
en dihydrouracil farmacokinetiek tussen vrijwilligers met een normale DPD-activiteit 
en DPD-deficiënte patiënten. Uracildoseringen groter dan 500 mg/m2 hebben geen beter 
onderscheidend vermogen om personen met en zonder DPD-deficiëntie te onderscheiden. 
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Verhoging van de uracildosering leidt alleen tot een rechtsverschuiving van de uracil- en 
dihydrouracil-concentratiecurve in de tijd en daardoor onnodige lange blootstelling aan 
hoge uracilconcentraties. 
Uracil wordt voornamelijk in de lever gemetaboliseerd en om deze reden zou de aanwezigheid 
van metastasen in de lever de kinetiek van uracil na toediening van de orale uracil 
belastingtest kunnen beïnvloeden. In hoofdstuk 5 wordt de uracildosering van 500 mg/m2 
lichaamsoppervlak verder bestudeerd en vergeleken in adjuvant behandelde patiënten met 
colonkanker en patiënten met colon/rectumkanker (CRC) met metastasen. De resultaten 
van deze studie laten zien dat in patiënten met normale DPD-activiteit, met de uitzondering 
van C
max
, er geen verschil is in uracil farmacokinetiek tussen patiënten met gemetastaseerd 
CRC ten opzichte van adjuvant behandelde colonkankerpatiënten. 
Het farmacokinetische profiel van uracil in deze twee studies is tot stand gekomen met 
behulp van een intensief bloedafnameschema dat niet ideaal is voor gebruik in een 
klinische setting. Om deze reden is in hoofdstuk 6 de orale uracil belastingtest verder 
onderzocht (i) om een vereenvoudigd bloedafnameschema te ontwikkelen, (ii) om 
verminderde uracileliminatie aan te tonen in patiënten met DPD-deficiëntie, (iii) om een 
verdiepende, kwantitatieve compartimentele farmacokinetiekanalyse uit te voeren op basis 
van uracil plasmaconcentraties. In dit onderzoek zijn verscheidene farmacokinetische 
parameters bepaald en met elkaar vergeleken. Dit heeft tot de conclusie geleid dat de uracil/
dihydrouracilratio op t = 120 min na de orale uracilinname de meest geschikte parameter is 
om patiënten die het risico lopen ernstige DPD-gerelateerde toxiciteit te ontwikkelen, met 
een hoge sensitiviteit en specificiteit te identificeren. 
De samenvatting van de productkenmerken van capecitabine vermeldt dat het gebruik 
gecontraïndiceerd is in patiënten met een bekende DPD-deficiëntie, gedefinieerd als 
zeldzame en onverwachte ernstige toxiciteit. Bij 5-FU geeft de samenvatting van de 
productkenmerken aan dat wanneer dat mogelijk is, de DPD enzymactiviteit gemeten 
zou moeten worden voor behandeling met 5-FU. Tot op heden wordt het vooraf screenen 
van DPD niet als standaardzorg beschouwd binnen de oncologie en wordt het niet 
beschreven in ESMO of Nederlandse richtlijnen. Dit kan een gevolg zijn van het feit dat er 
internationaal geen consensus is over de optimale strategie om patiënten te identificeren 
die het risico lopen ernstige DPD-gerelateerde toxiciteit te ontwikkelen. Desondanks zijn 
er goed georganiseerde initiatieven in een prospectieve setting waarbij DPD getest wordt. 














geëvalueerd in een Nederlands academisch centrum vooraf aan het voorschrijven van 5-FU 
of capecitabine. In deze studie werd de acceptatie van de voorschrijvers geëvalueerd om 
bij patiënten die 5-FU of capecitabine voorgeschreven kregen, prospectief DPYD te laten 
screenen en werd het opvolgen van de dosisadviezen onderzocht. Het aantal patiënten dat 
daadwerkelijk werd gescreend was met 86,9% relatief hoog en de dosisadviezen die door 
de apotheker werden afgegeven werden in de meeste gevallen opgevolgd. Deze studie toont 
aan dat het implementeren van DPYD-screenen in een prospectieve setting mogelijk is en 
dat implementatie in de dagelijkse praktijk succesvol kan plaatsvinden. 
In hoofdstuk 8 worden de resultaten van de studies in dit proefschrift bediscussieerd 
in een breed perspectief en worden toekomstige ontwikkelingen genoemd betreffende 
het verbeteren van de orale uracil belastingtest en het prospectief screenen van DPD in 
het algemeen. Los van de verdere ontwikkeling van de testprocedure, is de orale uracil 
belastingtest in de huidige vorm potentieel geschikt als een fenotyperende test om DPD-





Het mooie van een dankwoord is dat het de afronding van het promotietraject is en dat er 
bij het schrijven ervan teruggekeken kan worden op het traject dat is afgelegd. Hoewel vaak 
als laatste geschreven, is het grappig dat het dankwoord meestal als eerste wordt gelezen in 
een proefschrift. Het schrijven van dit dankwoord geeft mij een ontzettend voldaan gevoel 
vanwege het feit dat het promotietraject klaar is, maar er heerst er toch ook wel een gevoel 
van weemoed dat er een einde is gekomen aan een intrigerende periode vol ontdekkingen 
en resultaten. 
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ontzettend veel van jullie kunnen leren, dank daarvoor. 
Lieve Pa en Ma, wat een fijne jeugd heb ik gehad. Ik ben jullie zo dankbaar voor hoe 
jullie zijn en wat jullie voor mij hebben gedaan. Ik ben mede door jullie geworden wat 
ik nu ben en realiseer mij meer dan ooit dat de moeilijke jaren die wij als gezin hebben 
meegemaakt hebben geleid tot mijn doorzettingsvermogen, dit onderzoek en mijn keuze 
om ziekenhuisapotheker te worden. 
Paranimfen Roelof en Sander, het was voor mij een logische keuze om jullie te vragen om 
dit met mij te delen. Sander, wij kennen elkaar echt al ons leven lang, ik had je hierbij niet 
willen missen. Roelof, wij hebben elkaar goed leren kennen tijdens de oncologiedagen. Wij 
bleken het niet alleen professioneel maar ook privé goed met elkaar te kunnen vinden, net 
als onze gezinnen. Leuk dat we beide in 2016 ons promotietraject hebben afgerond.
Collega’s, bedankt voor al jullie enthousiasme en bereidheid om mij waar nodig vrij te 









Lieve, lieve Renate, mijn maatje, steun en toevertrouwen. Het waren tropenjaren. Samen 
met mij vader en moeder van onze jongens Max, Tim en Sam, ons grootste bezit. Jij bent er 
altijd voor mij en bent altijd geïnteresseerd in wat ik doe en vult mij aan. De afronding van 
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overlijden van je moeder wat voor een dubbel gevoel zorgt. Dit hoofdstuk van ons leven is 
nu af, we gaan verder met het beleven van  mooie nieuwe hoofdstukken.
Als laatste wil ik iedereen bedanken die hierboven niet genoemd wordt, maar wel een bijdrage 
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